BioRestorative Therapies (BRTX) 10-K 22 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 15, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 9,795,332
Entity Common Stock, Shares Outstanding		5,276,027
Trading Symbol	BRTX
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 31,822	$ 166,555
Accounts receivable	6,000	93,375
Prepaid expenses and other current assets	23,854	29,348
Total Current Assets	61,676	289,278
Property and equipment, net	508,594	643,087
Intangible assets, net	963,845	1,038,741
Security deposit	45,900	45,900
Total Assets	1,580,015	2,017,006
Current Liabilities:
Accounts payable	2,283,981	2,549,042
Accrued expenses and other current liabilities	1,574,659	2,046,795
Accrued interest	127,375	6,823
Current portion of notes payable, net of debt discount of $152,720 and $150,286 at December 31, 2016 and 2015, respectively	1,858,845	1,009,797
Total Current Liabilities	5,844,860	5,612,457
Accrued expenses, non-current portion	430,000
Accrued interest, non-current portion	7,681	11,011
Notes payable, non-current portion, net of debt discount of $27,244 and $7,999 at December 31, 2016 and 2015, respectively	297,756	302,001
Total Liabilities	6,580,297	5,925,469
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at December 31, 2016 and 2015
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued 4,699,035 and 3,338,661 shares at December 31, 2016 and 2015, respectively; Outstanding 4,699,035 and 3,310,729 shares at December 31, 2016 and 2015, respectively	4,699	3,339
Additional paid-in capital	36,954,817	29,443,704
Accumulated deficit	(41,959,798)	(33,323,506)
Treasury stock, at cost, 0 and 27,932 shares at December 31, 2016 and 2015, respectively		(32,000)
Total Stockholders' Deficiency	(5,000,282)	(3,908,463)
Total Liabilities and Stockholders' Deficiency	$ 1,580,015	$ 2,017,006

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 152,720	$ 150,286
Notes payable non-current, debt discount	$ 27,244	$ 7,999
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares Issued	4,699,035	3,338,661
Common stock, shares Outstanding	4,699,035	3,310,729
Treasury stock, at cost shares	0	27,932

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues	$ 36,355	$ 628,915
Cost of sales	102	261,504
Gross Profit	36,253	367,411
Operating Expenses
Marketing and promotion	86,451	168,352
Consulting	1,605,917	1,394,037
Research and development	2,883,563	2,105,059
General and administrative	3,257,579	3,870,325
Total Operating Expenses	7,833,510	7,537,773
Loss From Operations	(7,797,257)	(7,170,362)
Other Income (Expense)
Interest expense	(221,608)	(263,583)
Amortization of debt discount	(542,336)	(339,443)
Loss on extinguishment of notes payable, net	(58,787)	(35,677)
Warrant modification expense	(28,486)	(114,415)
Gain on settlement of payables	12,182
Total Other Expense	(839,035)	(753,118)
Net Loss	$ (8,636,292)	$ (7,923,480)
Net Loss Per Share - Basic and Diluted	$ (2.10)	$ (3.20)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	4,105,820	2,472,889

Condensed Consolidated Statemen

Condensed Consolidated Statement of Changes in Stockholders' Deficiency - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Common Stock [Member]
Balance	$ 3,339	$ 1,726
Balance, shares	3,338,661	1,725,596
Shares and warrants issued for cash	$ 956	$ 395
Shares and warrants issued for cash, shares	956,833	395,425
Exercise of warrants for purchase of common stock	$ 61	$ 76
Exercise of warrants for purchase of common stock, shares	60,831	75,473
Conversion of notes payable and accrued interest into common stock	$ 137	$ 54
Conversion of notes payable and accrued interest into common stock, shares	137,006	53,595
Shares issued in satisfaction of accrued services	$ 13	$ 1
Shares issued in satisfaction of accrued services, shares	13,208	943
Shares and warrants issued in connection with settlement agreement		$ 4
Shares and warrants issued in connection with settlement agreement, shares		4,230
Shares and warrants issued as debt discount in connection with notes payable	$ 6	$ 10
Shares and warrants issued as debt discount in connection with notes payable, shares	6,000	10,000
Shares and warrants issued in exchange of notes payable and accrued interest	$ 167	$ 1,028
Shares and warrants issued in exchange of notes payable and accrued interest, shares	167,027	1,028,237
Warrant modifications
Beneficial conversion features related to convertible notes payable
Stock-based compensation: - common stock	$ 55	$ 44
Stock-based compensation: - common stock, shares	54,901	43,698
Stock-based compensation: - options and warrants
Impact of share rounding as a result of reverse stock split		$ 1
Impact of share rounding as a result of reverse stock split, shares		1,464
Return of shares to treasury previously issued as compensation
Return of shares to treasury previously issued as compensation, shares
Retirement of treasury shares	$ (35)
Retirement of treasury share, shares	(35,432)
Net loss
Balance	$ 4,699	$ 3,339
Balance, shares	4,699,035	3,338,661
Additional Paid In Capital [Member]
Balance	$ 29,443,704	$ 18,541,907
Shares and warrants issued for cash	3,497,382	2,033,305
Exercise of warrants for purchase of common stock	212,837	264,068
Conversion of notes payable and accrued interest into common stock	341,615	238,454
Shares issued in satisfaction of accrued services	27,540	8,480
Shares and warrants issued in connection with settlement agreement		151,996
Shares and warrants issued as debt discount in connection with notes payable	246,206	178,883
Shares and warrants issued in exchange of notes payable and accrued interest	352,426	5,754,844
Warrant modifications	96,634	229,288
Beneficial conversion features related to convertible notes payable	231,708	87,788
Stock-based compensation: - common stock	116,903	177,603
Stock-based compensation: - options and warrants	2,436,702
Impact of share rounding as a result of reverse stock split		(1)
Return of shares to treasury previously issued as compensation
Return of shares to treasury previously issued as compensation, shares
Retirement of treasury shares	$ (48,840)
Net loss
Balance	36,954,817	29,443,704
Accumulated Deficit [Member]
Balance	(33,323,506)	(25,400,026)
Shares and warrants issued for cash
Exercise of warrants for purchase of common stock
Conversion of notes payable and accrued interest into common stock
Shares issued in satisfaction of accrued services
Shares and warrants issued in connection with settlement agreement
Shares and warrants issued as debt discount in connection with notes payable
Shares and warrants issued in exchange of notes payable and accrued interest
Warrant modifications
Beneficial conversion features related to convertible notes payable
Stock-based compensation: - common stock
Stock-based compensation: - options and warrants		7,923,480
Impact of share rounding as a result of reverse stock split
Return of shares to treasury previously issued as compensation
Retirement of treasury shares
Net loss	(8,636,292)	(7,923,480)
Balance	(41,959,798)	(33,323,506)
Treasury Stock [Member]
Balance	$ (32,000)	$ (32,000)
Balance, shares	(27,932)	(27,932)
Shares and warrants issued for cash
Exercise of warrants for purchase of common stock
Exercise of warrants for purchase of common stock, shares
Conversion of notes payable and accrued interest into common stock
Conversion of notes payable and accrued interest into common stock, shares
Shares issued in satisfaction of accrued services
Shares issued in satisfaction of accrued services, shares
Shares and warrants issued in connection with settlement agreement
Shares and warrants issued as debt discount in connection with notes payable
Shares and warrants issued in exchange of notes payable and accrued interest
Shares and warrants issued in exchange of notes payable and accrued interest, shares
Warrant modifications
Beneficial conversion features related to convertible notes payable
Stock-based compensation: - common stock
Stock-based compensation: - common stock, shares
Stock-based compensation: - options and warrants
Impact of share rounding as a result of reverse stock split
Return of shares to treasury previously issued as compensation	$ (16,875)
Return of shares to treasury previously issued as compensation, shares	(7,500)
Retirement of treasury shares	$ 48,875
Retirement of treasury share, shares	35,432
Net loss
Balance		$ (32,000)
Balance, shares		(27,932)
Balance	$ (3,908,463)	$ (6,888,393)
Shares and warrants issued for cash	3,498,338	2,033,700
Exercise of warrants for purchase of common stock	212,898	264,144
Conversion of notes payable and accrued interest into common stock	341,752	238,508
Shares issued in satisfaction of accrued services	27,553	8,481
Shares and warrants issued in connection with settlement agreement		152,000
Shares and warrants issued as debt discount in connection with notes payable	246,212	178,883
Shares and warrants issued in exchange of notes payable and accrued interest	352,593	5,755,872
Warrant modifications	96,634	229,288
Beneficial conversion features related to convertible notes payable	231,708	87,788
Stock-based compensation: - common stock	116,958	177,647
Stock-based compensation: - options and warrants	2,436,702	7,923,480
Impact of share rounding as a result of reverse stock split
Return of shares to treasury previously issued as compensation	(16,875)
Retirement of treasury shares
Net loss	(8,636,292)	(7,923,480)
Balance	$ (5,000,282)	$ (3,908,463)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities
Net loss	$ (8,636,292)	$ (7,923,480)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	542,336	339,443
Accretion of interest expense	40,052	85,086
Depreciation and amortization	258,425	213,784
Stock-based compensation	2,536,785	1,954,736
Loss on extinguishment of note payables, net	58,787	35,677
Warrant modification expense	28,486	114,415
Gain on settlement of payables	(12,182)
Changes in operating assets and liabilities:
Accounts receivable	87,375	(93,375)
Prepaid expenses and other current assets	5,494	(6,833)
Accounts payable	(113,151)	1,381,407
Accrued interest	120,552	(81,387)
Accrued expenses and other current liabilities	80,658	1,022,813
Deferred revenues		(164,349)
Total Adjustments	3,633,617	4,801,417
Net Cash Used In Operating Activities	(5,002,675)	(3,122,063)
Cash Flows From Investing Activities
Purchases of property and equipment	(188,764)	(408,069)
License maintenance costs		(75,000)
Net Cash Used In Investing Activities	(188,764)	(483,069)
Cash Flows From Financing Activities
Proceeds from notes payable	1,894,000	1,210,015
Repayments of notes payable	(476,500)	(5,000)
Advances from director, officer and family member of officer	292,090	564,105
Repayments of advances from an officer and a director	(364,120)	(387,075)
Proceeds from exercise of warrants	212,898	264,144
Sales of common stock and warrants for cash	3,498,338	2,033,700
Net Cash Provided By Financing Activities	5,056,706	3,679,889
Net (Decrease) Increase In Cash	(134,733)	74,757
Cash - Beginning	166,555	91,798
Cash - Ending	31,822	166,555
Supplemental Disclosures of Cash Flow Information:
Interest	30,406	61,453
Non-cash investing and financing activities:
Warrant modification in connection with extension or exchanges of notes payable	96,634	114,873
Shares and warrants issued as debt discount in connection with notes payable	246,212	178,893
Shares and warrants issued in exchange for notes payable, convertible notes and accrued interest	352,593	5,720,195
Conversion of notes payable and accrued interest into common stock	341,752	238,508
Shares issued in satisfaction of accrued consulting and director services	27,553	8,481
Accrued interest reclassified as principal in connection with note payable reissuance		44,379
Beneficial conversion features set up as debt discount	231,708	87,788
Shares and warrants issued in connection with settlement agreement		152,000
Accrued liabilities associated with purchases of property and equipment		139,729
Advances converted into note payable, related party		65,000
Indebtness satisfied via legal settlement		5,000
Retirement of treasury shares	$ 48,875

Business Organization, Nature o

Business Organization, Nature of Operations	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has two wholly-owned subsidiaries, Stem Pearls, LLC (“Stem Pearls”) and Stem Cell Cayman Ltd. (“Cayman”), which was formed in the Cayman Islands (collectively, “BRT” or the “Company”). On December 19, 2016, the Company submitted its request to the appropriate Cayman authorities for the dissolution of Cayman and is currently awaiting confirmation of the dissolution (See Note 3 – Summary of Significant Accounting Policies – Principles of Consolidation). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com. BRT is currently developing a Disc/Spine Program referred to as “brtxDISC”. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat metabolic disease and has labeled this initiative its “ThermoStem Program.” Through the program, BRT is developing a cell-based therapy to target type 2 diabetes, obesity and other metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Further, BRT has licensed a patented curved needle device that is a needle system to allow access to difficult to locate regions for the delivery or removal of fluids and other substances. BRT’s Stem Pearls brand offers plant stem cell-based cosmetic skincare products that are available for purchase online at www.stempearls.com. Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split of the Company’s issued and outstanding common stock (the “Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 200,000,000 to 30,000,000. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented.

Going Concern and Management's

Going Concern and Management's Plans	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2 – Going Concern and Management’s Plans As of December 31, 2016, the Company had a working capital deficiency and a stockholders’ deficiency of $5,783,184 and $5,000,282, respectively. During the years ended December 31, 2016 and 2015, the Company incurred net losses of $8,636,292 and $7,923,480, respectively. These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern for at least the next twelve months from the filing date of this report. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to December 31, 2016, the Company has received aggregate equity proceeds (including proceeds from the exercise of common stock purchase warrants) and debt proceeds of $945,000 and $200,000, respectively, debt and accrued interest of $325,000 and $9,679, respectively, has been converted into or exchanged for common stock, $89,000 of debt and net short-term advances have been repaid and the due date for the repayment of $322,000 of debt has been extended through April 2017. As a result, the Company expects to have the cash required to fund its operations through April 2017. While there can be no assurance that it will be successful, the Company is in negotiations to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $427,500 which are past due. The Company is currently in the process of negotiating extensions or discussing conversions to equity with respect to these notes. However, there can be no assurance that the Company will be successful in extending or converting these notes. See Note 11 – Subsequent Events for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. As discussed above, the Company is in the process of dissolving Cayman, which had no material assets, liabilities or operations (other than intercompany balances) and is no longer needed to facilitate certain financings. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Concentrations Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2015. One license comprised substantially all of the Company’s revenue during the year ended December 31, 2016. See Revenue Recognition – Research and Development Agreements below. Cash The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts, periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. Intangible Assets Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 and 17.7 years, respectively. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight-line basis. Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. While the Company’s near term liquidity is tight, historically the Company has been successful in raising capital as needed (although there can be no assurance that the Company will continue to be successful in raising capital as needed). The Company continues to progress its scientific agenda and meet related milestones. The Company has not identified any impairment losses. Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. As of December 31, 2015, the Company completed all of its obligations under research and development agreements entered into during 2014. During the years ended December 31, 2016 and 2015, the Company recognized $0 and $609,490, respectively, related to the Company’s research and development agreements. Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. In November 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the years ended December 31, 2016 and 2015, the Company recognized $36,000 and $19,000, respectively, of revenue related to the Company’s sublicense agreements. During the years ended December 31, 2016 and 2015, the Company recognized revenue related to sales of Stem Pearls skincare products of $355 and $425, respectively, with a related cost of sales of $102 and $54, respectively. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2016 and 2015. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2016 2015 Options 2,168,950 1,330,450 Warrants 2,953,651 1,066,930 Convertible notes 211,162 148,708 Total potentially dilutive shares 5,333,763 2,546,088 Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Advertising Advertising costs are charged to operations as incurred. For the years ended December 31, 2016 and 2015, the Company incurred advertising costs of $17,972 and $23,467, respectively. Advertising expense is reflected in marketing and promotion expenses in the consolidated statements of operations. Research and Development Research and development expenses are charged to operations as incurred. For the years ended December 31, 2016 and 2015, the Company incurred research and development expenses of $2,883,563 and $2,105,059, respectively. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short–term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk. Convertible Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. To allow entities additional time to implement systems, gather data and resolve implementation questions, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, in August 2015, to defer the effective date of ASU No. 2014-09 for one year, which is fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements or disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and annual and interim periods thereafter, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s financial statement disclosures. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”, or ASU 2015-03. ASU 2015-03 amends the existing guidance to require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related debt liability instead of as a deferred charge. ASU 2015-03 is effective on a retrospective basis for annual and interim reporting periods beginning after December 15, 2015; earlier adoption is permitted. Additionally, in August 2015 the FASB issued guidance expanding the April 2015 update (ASU No. 2015-15). It states that, given the absence of authoritative guidance within the update, the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset for revolving lines of credit and subsequently amortizing the deferred debt issuance costs ratably over the term of the arrangement, regardless of whether there are any outstanding borrowings on the line of credit. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years, with early adoption permitted for financial statements that have not been previously issued. Full retrospective application is required. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating ASU 2016-09 and its impact on its consolidated financial statements or disclosures. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The amendments in this update clarify the following two aspects to Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. The entity first identifies the promised goods or services in the contract and reduces the cost and complexity. An entity evaluates whether promised goods and services are distinct. Topic 606 includes implementation guidance on determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). ASU 2016-10 is effective for fiscal years beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company is currently evaluating ASU 2016-10 and its impact on its consolidated financial statements or disclosures. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017. The Company will require adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its consolidated financial statements or disclosures.

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 4 – Property and Equipment, net Property and equipment include the following: December 31, 2016 2015 Office equipment $ 2,848 $ 9,494 Medical equipment 446,506 418,280 Furniture and fixtures 121,625 126,150 Computer software and equipment 74,572 85,118 Leasehold improvements 304,661 301,610 950,212 940,652 Less: accumulated depreciation (441,618 ) (297,565 ) Property and equipment, net $ 508,594 $ 643,087 During the year ended December 31, 2016, the Company disposed of fully depreciated property and equipment in the amount of $39,476. Depreciation expense amounted to $183,529 and $139,793 for the years ended December 31, 2016 and 2015, respectively. Depreciation expense is reflected in general and administrative expenses and research and development expenses in the consolidated statement of operations.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5 – Intangible Assets On January 27, 2012, the Company entered into a license agreement with the SCTC (as amended in March 2012 and November 2015, the “SCTC Agreement”). On April 6, 2012 (the “Closing Date”), the Company and SCTC closed on the SCTC Agreement. Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from SCTC to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. On March 5, 2015, the Company made a $75,000 cash payment to retain the exclusivity of the license. Pursuant to the license agreement with SCTC, unless certain performance milestones are or have been satisfied, the Company would be required to pay to SCTC $150,000 by April 2017 and an additional $250,000 by April 2019 in order to maintain its exclusive rights with regard to the disc/spine technology. In February 2017, in connection with the Company receiving clearance from the Food and Drug Administration (the “FDA”) to proceed with a Phase 2 clinical trial, the Company believes that it has satisfied a performance milestone such that the Company would no longer be required to pay to the STC a minimum amount of $150,000 by April 2017 to retain exclusive rights with regard to the disc/spine technology. Intangible assets consist of the following: Patents and Trademarks Licenses Accumulated Amortization Total Balance as of January 1, 2015 $ 3,676 $ 1,226,500 $ (192,444 ) $ 1,037,732 Additions - 75,000 - 75,000 Amortization expense - - (73,991 ) (73,991 ) Balance as of December 31, 2015 3,676 1,301,500 (266,435 ) 1,038,741 Amortization expense - - (74,896 ) (74,896 ) Balance as of December 31, 2016 $ 3,676 $ 1,301,500 $ (341,331 ) $ 963,845 Weighted average remaining amortization period at December 31, 2016 in years 4.0 12.9 Amortization of intangible assets consists of the following: Patents and Trademarks Licenses Accumulated Amortization Balance as of January 1, 2015 $ 1,472 $ 190,972 $ 192,444 Amortization expense 368 73,623 73,991 Balance as of December 31, 2015 1,840 264,595 266,435 Amortization expense 368 74,528 74,896 Balance as of December 31, 2016 $ 2,208 $ 339,123 $ 341,331 Amortization expense is reflected in general and administrative expenses in the consolidated statements of operations. Based upon the current intangible assets as of December 31, 2016, amortization expense is projected to be approximately $75,000 per annum through 2029.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 6 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: December 31, 2016 2015 Credit card payable $ 1,778 $ 3,171 Accrued payroll 880,293 1,010,633 Advances from related parties - 87,030 Accrued research and development expenses 406,175 446,175 Accrued general and administrative expenses 233,468 456,182 Deferred rent 52,945 43,604 Accrued expenses, current portion 1,574,659 2,046,795 Accrued expenses, non-current portion 430,000 - Total accrued expenses $ 2,004,659 $ 2,046,795 During the year ended December 31, 2016, the Company received an aggregate of $292,090 in non-interest bearing advances from an officer, directors and a consultant of the Company and made aggregate repayments of $364,120. During the year ended December 31, 2015, the Company received an aggregate of $564,105 in non-interest bearing advances from an officer, directors, a family member of an officer and a consultant of the Company and made aggregate repayments of $387,075, converted a related party advance in the amount of $65,000 into a non-interest bearing note payable in the principal amount of $75,000 with a maturity date of October 30, 2015 (see Note 7) and, in December 2015, exchanged an advance in the amount of $25,000 for 6,250 shares of common stock valued at $14,063 and a five-year warrant to purchase 6,250 shares of common stock at an exercise price of $4.00 per share with a grant date value of $11,063. During the year ended December 31, 2015, the Company recognized a $126 loss on the extinguishment of the advance in connection with the exchange for the shares of common stock and a warrant. As of December 31, 2016, the Company reclassified accrued expenses in the aggregate amount of $255,000 to accrued expenses, non-current portion, on the consolidated balance sheets related to accrued consulting and directors fees that were exchanged for shares of common stock and warrants subsequent to December 31, 2016. See Note 11 – Subsequent Events for additional details regarding the exchange of accrued consulting and directors fees

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	Note 7 – Notes Payable A summary of the notes payable activity during the years ended December 31, 2016 and 2015 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, January 1, 2015 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257 ) $ 5,738,239 Issuances 150,000 735,000 [1] 478,018 [1] - 1,363,018 Indebtedness satisfied via settlement - - (5,000 ) - (5,000 ) Exchanges for equity (4,410,937 ) (266,667 ) (877,873 ) - (5,555,477 ) Conversions to equity - (223,333 ) - - (223,333 ) Repayments - - (5,000 ) - (5,000 ) Recognition of debt discount - - - (469,557 )[1] (469,557 ) Accretion of interest expense - - - 85,086 [1] 85,086 Amortization of debt discount - - - 339,443 339,443 Recharacterization of accrued interest as principal - - 44,379 [2] - 44,379 Outstanding, December 31, 2015 $ 150,000 $ 420,000 [3] $ 900,083 $ (158,285 ) $ 1,311,798 Issuances 697,500 530,000 724,500 [1] - 1,952,000 Indebtedness satisfied via settlement - - - - - Exchanges for equity - (235,000 ) (49,018 ) - (284,018 ) Conversion to equity - (325,000 ) - - (325,000 ) Repayments (150,000 ) - (326,500 ) - (476,500 ) Recognition of debt discount - - - (604,067 )[1] (604,067 ) Accretion of interest expense - - - 40,052 [1] 40,052 Amortization of debt discount - - - 542,336 542,336 Outstanding, December 31, 2016 $ 697,500 $ 390,000 [3] $ 1,249,065 $ (179,964 ) $ 2,156,601 Outstanding, December 31, 2015 $ 150,000 $ 420,000 $ 900,083 $ (158,285 ) $ 1,311,798 Less: current portion, December 31, 2015 (150,000 ) (110,000 ) (900,083 ) 150,286 (1,009,797 ) Non-current portion, December 31, 2015 [4] $ - $ 310,000 $ - $ (7,999 ) $ 302,001 Outstanding, December 31, 2016 $ 697,500 $ 390,000 $ 1,249,065 $ (179,964 ) $ 2,156,601 Less: current portion, December 31, 2016 (430,000 ) (345,000 ) (1,236,565 ) 152,720 (1,858,845 ) Non-current portion, December 31, 2016 [4] $ 267,500 $ 45,000 $ 12,500 $ (27,244 ) $ 297,756 [1] During the years ended December 31, 2016 and 2015, notes with an aggregate principal amount of $432,000 and $538,018, respectively, bear no interest and were issued for cash consideration of $374,000 and $450,015, respectively. The difference between the principal amount of the notes and the cash received of $58,000 and $88,003, respectively, was recorded as debt discount and is being accreted to interest expense over the term of the notes. During the year ended December 31, 2015 the Company issued a note payable in the principal amount of $75,000 for a short-term advance from a related party in the amount of $65,000. [2] During the year ended December 31, 2015, in connection with the extension of certain notes payable, an aggregate of $44,379 of accrued interest was added to the aggregate principal balance of the notes. [3] As of December 31, 2016 and 2015, a designated portion of convertible notes with an aggregate principal balance of $390,000 and $420,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $296,250 and $197,500, respectively, of principal into shares of common stock. [4] As of December 31, 2016 and 2015, the Company reclassified principal in the aggregate amount of $297,756 and $302,001, respectively (net of debt discount of $27,244 and $7,999, respectively) and accrued interest in the aggregate amount of $7,681 and $11,011, respectively to notes payable, non-current portion, net of debt discount and accrued interest, non-current portion, respectively, on the consolidated balance sheets related to outstanding notes payable that were converted into or exchanged for shares of common stock and warrants subsequent to December 31, 2016 and 2015, respectively. See Note 11 – Subsequent Events for additional details regarding notes payable. Related Party Notes In May 2015, Cayman and a single entity (the “Bermuda Lender”) agreed to extend the maturity date of a note payable in the original principal amount of $500,000 (the “$500,000 Bermuda Lender Note”) (with an outstanding principal balance of $410,937) from May 7, 2015 to June 30, 2015 (the “New Maturity Date”). The Bermuda Lender waived any and all defaults under the $500,000 Bermuda Lender Note, including with respect to the failure by the Company to pay to the Bermuda Lender, pursuant to the $500,000 Bermuda Lender Note, the aggregate amount of $316,297 received by the Company from its research and development agreements. In May 2015, the Company and the Bermuda Lender agreed to exchange the $500,000 Bermuda Lender Note and a note payable to the Bermuda Lender in the principal amount of $4,000,000 (with an aggregate principal amount of $4,410,937 and aggregate accrued interest of $69,436) for 746,730 shares of common stock with a grant date value of $3,733,645 and an immediately vested five-year warrant to purchase 186,682 shares of common stock at an exercise price of $15.00 per share with a grant date fair value of $672,056. In connection with the exchange, the Company extended the expiration date of a previously outstanding warrant to purchase 40,000 shares of common stock from December 31, 2015 to December 31, 2017 and recognized a warrant modification charge of $80,000, which represents the incremental value of the modified warrant and new warrant combined, as compared to the original warrant value, both valued as of the modification date. During the year ended December 31, 2015, the Company recognized a $5,327 loss on the extinguishment of notes payable in connection with the exchange for the shares of common stock and a warrant. In October 2015, the Company borrowed $150,000 from an affiliate of the Bermuda Lender and issued to the affiliate a two month note in the principal amount of $150,000. The note provided for interest at a rate of 10% per annum and that, in the event that, prior to the maturity date, the Company received any proceeds from a public equity offering or monies in payment of an accounts receivable, then, the Company would be obligated to prepay the principal and interest on a dollar-for-dollar basis to the extent of such monies so received, but not to exceed the outstanding principal and interest balance of the note. The note was secured by a security interest in a patent held by the Company associated with its brown fat program. In December 2015, the Company and the affiliate of the Bermuda Lender extended the maturity date of the note to March 9, 2016. In connection with the extension, the Company reduced the exercise price of warrants to purchase an aggregate 239,182 shares of common stock held by the Bermuda Lender from $15.00 per share to $4.00 per share. As a result of the warrant modification, the Company recognized $98,739 of debt discount which will be amortized over the term of the note. In July 2016, the Company repaid the $150,000 outstanding balance of the note. As of December 31, 2016 and 2015, the Bermuda Lender was a related party as a result of having in excess of a 10% beneficial ownership interest in the Company's common stock. On June 30, 2016, the Company borrowed $500,000 from Tuxis Trust (the "Trust"). A director and principal shareholder of the Company serves as a trustee of the Trust, which was established for the benefit of his immediate family. The promissory note evidencing the loan provides for the payment of the principal amount, together with interest at the rate of 10% per annum, on July 1, 2017. In the event that, prior to maturity, the Company receives net proceeds of $10,000,000 from a single equity or debt financing (as opposed to a series of related or unrelated financings), the Trust has the right to require that the Company prepay the amount due under the note (subject to the consent of the party that provided the particular financing). In consideration of the loan, the Company issued to the Trust a five-year, immediately vested warrant for the purchase of 40,000 shares of common stock of the Company at an exercise price of $4.00 per share. The $55,659 relative fair value of the warrant has been recorded as debt discount and will be amortized over the term of the note During the year ended December 31, 2016, the Company issued notes payable with an aggregate principal balance of $197,500 for aggregate cash consideration of $190,000 to directors of the Company. The notes mature on dates ranging from January 31, 2017 to February 5, 2017 and range from bearing no interest to 10% interest per annum, payable monthly. The $7,500 difference between the principal amount of the notes and the cash received was recorded as debt discount and is being amortized to interest expense over the term of notes. In connection with the note issuances, t See Note 10 – Stockholders’ Deficiency – Warrant and Option Valuation and Note 10 – Stockholders’ Deficiency – Stock Warrants regarding details for the valuation of warrants and the Black-Scholes valuation assumptions. Convertible Notes Issuances During the year ended December 31, 2015, the Company issued convertible notes with an aggregate principal balance of $735,000 for aggregate cash consideration of $725,000. The convertible notes matured between July 2015 and June 2016 and accrued interest at rates ranging from 1% to 12% per annum payable at maturity. The $10,000 difference between the principal amount of the convertible notes and the cash received was recorded as debt discount and was amortized to interest expense over the term of the convertible notes. The convertible notes were convertible into shares of the Company’s common stock at the election of the Company during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 55% to 65% of the fair value of the Company’s common stock or (b) $2.00 or $3.00 per share depending on the note. With respect to $272,500 principal amount of the notes, in the event that the Company elected to convert a portion of the principal outstanding under the notes into common stock, the holder had the right to convert up to the remaining principal into shares of common stock at the conversion price. In connection with the issuance of the convertible notes, the Company issued five-year, immediately vested warrants to purchase an aggregate of 30,885 shares of common stock at exercise prices ranging from $5.00 to $10.00 per share. The aggregate relative fair value of the warrants of $90,018 has been recorded as debt discount and was amortized over the term of the convertible notes. See “Conversions, Exchanges, and Other” below. During the year ended December 31, 2016, the Company issued convertible notes with an aggregate principal balance of $530,000 which mature on dates ranging from September 2016 to August 2017 and accrue interest at 10% per annum payable at maturity. The convertible notes are convertible into shares of the Company’s stock at the election of the Company during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 60% to 62% of the fair value of the Company’s common stock or (b) $0.75, $1.00, or $2.00 per share depending on the note, With respect to $296,250 principal amount of the notes, in the event that the Company elects to convert a portion of the principal outstanding under the notes into common stock, the holder will have the right to convert up to the remaining principal into shares of common stock at the conversion price. In connection with the issuance of convertible notes, the Company issued five-year, immediately vested warrants to purchase an aggregate of 33,750 shares of common stock at an exercise price of $4.00 per share. The aggregate relative fair value of the $53,150 has been recorded as debt discount and is being amortized over the term of the convertible notes. Conversions, Exchanges and Other During the year ended December 31, 2015, the Company elected to convert certain convertible notes with an aggregate principal balance of $223,333 and aggregate accrued interest of $15,175 into an aggregate of 53,595 shares of common stock at conversion prices ranging from $3.00 to $5.16 per share. During the year ended December 31, 2015, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $266,667, along with accrued and unpaid interest of $12,580, for an aggregate of 92,875 shares of common stock and immediately vested, five-year warrants to purchase an aggregate of 39,092 shares of common stock at an exercise price of $4.00 per share. The common stock and warrants had an aggregate grant date value of $288,060 and, as a result, the Company recorded a loss on extinguishment of $8,813. During the year ended December 31, 2016, the Company elected to convert certain convertible notes with an aggregate principal balance of $325,000 and aggregate accrued interest of $16,751 into an aggregate of 137,006 shares of common stock at conversion prices ranging from $1.94 to $3.00 per share. During the year ended December 31, 2016, the Company and certain lenders agreed to exchange certain convertible notes with an aggregate principal balance of $235,000, along with accrued and unpaid interest of $9,788, for an aggregate of 143,102 shares of common stock at prices ranging from $1.50 to $2.10 per share. The common stock had an aggregate issuance date value of $298,762 and, as a result, the Company recorded a loss on extinguishment of $53,974. During the years ended December 31, 2016 and 2015, the contingently adjustable conversion ratio associated with certain convertible notes was resolved and such notes became convertible during the period. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the years ended December 31 2016 and 2015, the Company recognized $231,708 and $87,788, respectively, related to the beneficial conversion feature as debt discount which was immediately amortized. As of December 31, 2016, the outstanding convertible notes have maturity dates ranging from February 2017 to August 2017 and predominantly bear interest at a rate of 10% per annum payable at maturity. See Note 10 – Stockholders’ Deficiency – Warrant and Option Valuation and Note 10 – Stockholders’ Deficiency – Stock Warrants regarding details for the valuation of warrants and the Black-Scholes valuation assumptions. Other Notes Issuances During the year ended December 31, 2015, the Company issued other notes payable with an aggregate principal amount of $478,018 for aggregate cash consideration of $400,015, including the issuance of a note payable in the principal amount of $75,000 for a short-term advance from a related party in the amount of $65,000. The notes issued had maturity dates between October 2015 and December 2015, bore no interest and the $78,003 difference between the aggregate principal amount of the notes and the cash received was recorded as debt discount and was amortized to interest expense over the term of the notes. During the year ended December 31, 2016, the Company issued other notes payable with an aggregate principal amount of $724,500 for aggregate cash consideration of $674,000. The notes issued have maturity dates ranging from September 2016 to April 2017, interest rates ranging from bearing no interest to 10% per annum, payable at maturity, and the $58,000 difference between the principal amount of the notes and the cash received was recorded as debt discount and is being amortized to interest expense over the term of notes. In connection with the issuance of the notes, the Company issued five-year, immediately vested warrants to purchase an aggregate of 39,000 shares of common stock at an exercise price of $4.00 per share. The aggregate $61,767 relative fair value of the warrants has been recorded as debt discount and is being amortized over the term of the notes. Exchanges and Other During the year ended December 31, 2015, the Company and certain lenders agreed to exchange certain other notes with an aggregate principal balance of $877,873, along with accrued and unpaid interest of $82,701, for an aggregate of 188,632 shares of common stock and five-year warrants to purchase an aggregate of 111,358 shares of common stock at exercises ranging from $4.00 to $15.00 per share. The stock and warrants had an aggregate issuance date value of $982,112 and, as a result, the Company recorded a loss on extinguishment of $21,537. During the year ended December 31, 2015, the Company extended certain other notes payable in the aggregate principal amount of $735,081 from maturity dates ranging from October 2015 to December 2015 to new maturity dates ranging from December 2015 to October 2016. In connection with the extension of other notes, the Company issued the lenders an aggregate of 10,000 shares of common stock and five-year warrants to purchase an aggregate of 37,500 shares of common stock at an exercise prices of $4.00 per share. The aggregate grant date fair value of the shares and warrants of $88,875 has been recorded as debt discount and was amortized over the terms of the notes. Additionally, in connection with a certain other note extension, the Company reduced the exercise price of warrants held by a certain lender to purchase an aggregate of 35,215 shares of common stock from $10.00 per share to $4.00 per share. In connection with the warrant modifications, the Company recognized $10,234 of deferred debt discount which was amortized over the term of the extended note. During the year ended December 31, 2015, the Company repaid an aggregate principal balance of $5,000 related to certain other notes. During the year ended December 31, 2015, the Company and a lender agreed that a certain other note payable held by the lender in the principal amount of $5,000 was to be extinguished in connection with the terms of a settlement agreement. See Note 9 – Commitments and Contingencies – Litigation for additional details. During the year ended December 31, 2016, the Company and certain lenders agreed to exchange certain other notes with an aggregate principal balance of $49,018 for an aggregate of 23,925 shares of common stock at prices ranging from $1.25 to $2.45 per share. The common stock had an aggregate issuance date value of $53,831 and, as a result, the Company recorded a loss on extinguishment of $4,813. During the year ended December 31, 2016, the Company and a lender agreed to multiple extensions of the maturity date of a non-interest bearing note payable in the original principal amount of $244,000 from February 5, 2016 to July 15, 2016. In connection with the extensions, the Company (i) paid the lender an aggregate of $111,000 of which $96,000 was repayment of the principal balance and $15,000 was a fee related to the extension which is reflected within interest expense in the consolidated statements of operations, (ii) the lender received 6,000 shares of common stock with a fair value of $13,500 which was recorded as debt discount and amortized over the term of the extension and (iii) the Company and the lender agreed to exchange principal in the amount of $10,000 into 8,000 shares of common stock (included within the exchanges discussed above). On July 15, 2016, the Company repaid the $138,000 outstanding principal balance. During the year ended December 31, 2016, excluding amounts extended as discussed above, the Company extended notes payable with an aggregate principal balance of $567,063 from maturity dates within October 2015 to new maturity dates ranging from August 2016 to October 2017. In connection with one of the notes extended, the Company issued a five-year, immediately vested warrant to purchase 30,000 shares at an exercise price of $4.00 per share. The $52,800 relative fair value of the warrant has been recorded as debt discount and is being amortized over the term of the note. Additionally, outstanding warrants to purchase an aggregate of 60,215 shares of common stock with an exercise price of $4.00 and expiration dates ranging from June 2017 to December 2020 had their expiration dates extended to October 2021. In connection with the warrant modifications, the Company recognized $13,120 of deferred debt discount which is being amortized over the term of the extended note. During the year ended December 31, 2016, excluding amounts repaid as discussed above, the Company repaid an aggregate principal amount of $92,500 of notes payable. As of December 31, 2016, the outstanding other notes have maturity dates ranging from past due to October 1, 2017 and bear interest at rates ranging from 0% to 15% payable at maturity. The holder of one of the notes is entitled to five years of royalty payments associated with cosmetic revenues, as defined in the note, ranging from 2.0% to 4.0% of cosmetic revenues, depending on the year the cosmetic revenues are earned. Given that the Company has not yet generated any cosmetic revenues, no royalty payments have been earned. See Note 10 – Stockholders’ Deficiency – Warrant and Option Valuation and Note 10 – Stockholders’ Deficiency – Stock Warrants regarding details for the valuation of warrants and the Black-Scholes valuation assumptions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 – Income Taxes United States and foreign components of loss before income taxes were as follows: For The Years Ended December 31, 2016 2015 United States $ (8,627,380 ) $ (7,767,924 ) Foreign (8,912 ) (155,556 ) Loss before income taxes $ (8,636,292 ) $ (7,923,480 ) The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below: For The Years Ended December 31, 2016 2015 Deferred Tax Assets: Net operating loss carryforward $ 3,495,000 $ 1,181,900 Stock-based compensation 2,868,000 1,976,600 Accruals 237,000 231,100 Research & development tax credits 192,000 139,480 Other 2,000 2,100 Gross deferred tax assets 6,794,000 3,531,180 Deferred Tax Liabilities: Fixed assets (97,000 ) (110,300 ) Intangible assets (18,000 ) (13,400 ) Gross deferred tax liabilities (115,000 ) (123,700 ) Net deferred tax assets 6,679,000 3,407,480 Valuation allowance (6,679,000 ) (3,407,480 ) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ 3,271,520 $ (2,922,620 ) The income tax provision (benefit) consists of the following: For The Years Ended December 31, 2016 2015 Federal: Current $ - $ - Deferred (2,927,149 ) 2,614,976 State and local: Current - - Deferred (344,371 ) 307,644 (3,271,520 ) 2,922,620 Change in valuation allowance 3,271,520 (2,922,620 ) Income tax provision (benefit) $ - $ - A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For The Years Ended December 31, 2016 2015 Tax benefit at federal statutory rate (34.0 )% (34.0 )% State income taxes, net of federal benefit (4.0 )% (4.0 )% Permanent differences 0.4 % 0.8 % Research & development tax credits (0.6 )% (0.6 )% Impact of Section 382 limit 0.0 % 76.0 % True-ups and other 0.3 % (0.6 )% Change in valuation allowance 37.9 % (37.6 )% Effective income tax rate 0.0 % 0.0 % The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized. At December 31, 2016 and 2015, the Company had approximately $9,200,000 and $3,100,000, respectively, of federal net operating losses that may be available to offset future taxable income. State net operating losses are not materially different from the federal net operating losses. The net operating loss carry forwards, if not utilized, will expire from 2029 to 2036 for federal purposes. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carry forwards are subject to annual limitations due to greater than 50% ownership changes. The Section 382 limitations that became effective on or about August 2015 and July 2014 have resulted in (a) approximately $15,500,000 and $5,700,000, respectively, of federal NOLs not being realizable; and (b) the reversal of approximately $5,900,000 and $2,200,000, respectively, of net operating loss deferred tax assets. The Company files income tax returns in the U.S. federal jurisdiction and the state of New York (also formerly Florida), which remain subject to examination by the various taxing authorities beginning with the tax year ended December 31, 2013.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Operating Lease The Company is a party to a lease for 6,800 square feet of space located in Melville, New York (the “Melville Lease”) with respect to its corporate and laboratory operations. The Melville Lease expires in March 2020 (subject to extension at the option of the Company for a period of five years) and calls for an annual base rental during the initial term ranging between $132,600 and $149,260. The aggregate base rent payable over the lease term will be recognized on a straight-line basis. In connection with the operating lease, the Company paid the landlord a security deposit of $45,900, which is reflected on the consolidated balance sheet as of December 31, 2016 and 2015. During the year ended December 31, 2016, the Company received a credit of $20,912 towards its 2016 rent payments in connection with a tax rebate received by the landlord. The Company’s rent expense amounted to $124,038 and $141,131 for the years ended December 31, 2016 and 2015, respectively. Rent expense is reflected in general and administrative expenses and research and development expenses in the consolidated statement of operations. Future minimum payments under this operating lease agreement is as follows: For the Years Ending, December 31, Amount 2017 $ 127,948 2018 131,778 2019 148,172 2020 37,315 $ 445,213 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In April 2015, the Company and an alleged former consultant entered into a settlement agreement regarding an action commenced against the Company in the Circuit Court of Palm Beach County, Florida by the plaintiff. In connection with the settlement agreement, during the year ended December 31, 2015, in addition to certain cash payment obligations, the Company issued the plaintiff 4,230 shares of common stock and five-year, immediately vested warrants to purchase an aggregate of 30,000 shares of common stock at exercise prices ranging from $7.60 to $12.00 per share in full satisfaction of the claims. The aggregate value of the issuances of $152,000 was recognized immediately. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Research Agreements In June 2015, a research agreement entered into in June 2012 between the Company and the research foundation of a state university expired. During the year ended December 31, 2015, the Company recorded research and development expense of approximately $103,000 in connection with the research agreement. As of December 31, 2016, the Company had accrued approximately $112,000, in connection with the research agreement, which is included in accrued expenses and other current liabilities in the consolidated balance sheets. Consulting Agreements Business Advisory Services In August 2015, a February 2011 agreement for business advisory services that had expired on June 30, 2015 was further amended. Pursuant to the amendment, the agreement was reinstated effective as of July 1, 2015 and provided for an expiration date of June 30, 2016 (the “New Business Advisory Extended Term”). In June 2016, the agreement was further amended and the agreement was reinstated effective as of July 1, 2016 and provided for an expiration date of December 31, 2016 (the “New Business Advisory Extended Term”). In consideration of services rendered during the New Business Advisory Extended Term, the Company agreed to pay a cash fee of $15,000 per month and the Company granted an immediately vested five-year warrant to purchase 10,000 shares of common stock at an exercise price of $12.00 per share and an immediately vested five-year warrant to purchase 10,000 shares of common stock at an exercise price of $10.00 per share. The aggregate grant date value of the warrants of $74,923 was recognized immediately. During each of the years ended December 31, 2016 and 2015, the Company recorded cash consulting fee expense of $180,000 related to the business advisory agreement. See Note 10 – Stockholders’ Deficiency – Warrant and Option Valuation and Note 10 – Stockholders’ Deficiency – Stock Warrants regarding details for the valuation of warrants and the Black-Scholes valuation assumptions. Employment Agreements Chief Executive Officer In March 2015, the Company and its Chief Executive Officer (“CEO”) agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum and, effective January 1, 2015, the CEO’s annual car allowance was reduced to $7,200 from $14,400. Pursuant to the employment agreement, the CEO was entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and is entitled to receive an annual bonus for each of 2016 and 2017 of up to 50% of his annual base salary in the event certain performance goals, as determined by the Compensation Committee of the Board of Directors of the Company(the “Compensation Committee”), are satisfied. In February 2017, the Compensation Committee and the CEO agreed to amend the CEO’s 2016 annual bonus such that (i) the total bonus that could be earned would be equal to 40% of the CEO’s 2016 annual salary and (ii) the CEO would have until July 31, 2017 to satisfy certain performance goals related to his 2016 bonus. Pursuant to the employment agreement, in the event that (a) the CEO’s employment is terminated by the Company without cause, or (b) the CEO terminates his employment for “good reason” (each as defined in the employment agreement), or (c) the term of the CEO’s employment agreement is not extended beyond December 31, 2017 and, within three months of such expiration date, his employment is terminated by the Company without “cause” or the CEO terminates his employment for any reason, the CEO would be entitled to receive severance in an amount equal to his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus). Further, in the event that the CEO’s employment is terminated by the Company without cause, or the CEO terminates his employment for “good reason”, following a “change in control” (as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus). During each of the years ended December 31, 2016 and 2015, the Company recorded $407,200 in operating expenses with regard to the CEO’s base salary and car allowance. As of December 31, 2016 and 2015, the accrued and unpaid compensation (salary, bonus, tax liability, car allowance and vacation pay) for the CEO was $602,221 and $797,576, respectively, and was included in accrued expenses and other current liabilities in the consolidated balance sheets. As of December 31, 2016, the Company has accrued $96,000 and $49,691 for CEO bonus payments which have been achieved or are probable to be achieved over the service period, respectively. Other During the year ended December 31, 2016, the Company’s Compensation Committee and Board of Directors approved performance-based cash bonuses for the year ended December 31, 2016 for the Company’s officers and certain employees in the aggregate amount of up to $225,750, excluding amounts earnable by the Company’s CEO. In March 2017, the Company’s Board of Directors approved amendments of the performance-based cash bonuses for the year ended December 31, 2016 for the Company’s officers (other than the CEO, as discussed above) and certain current employees such that (i) an aggregate of up to $162,000, excluding amounts earnable by the Company’s CEO, could be earned pursuant to the satisfaction of certain 2016 performance goals and (ii) the Company’s officers and certain employees would have until July 31, 2017 to satisfy certain performance goals related to cash bonuses for the year ended December 31, 2016. As of December 31, 2016, excluding amounts due to the Company’s CEO as discussed above, the Company has accrued $95,041 and $50,531 for bonus payments which have been achieved or are probable to be achieved over the service period, respectively. In February 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and bonus. In the event the Company terminates the Division President’s employment without cause, the Division President is entitled to cash severance payments equal to one-half of his then annual base salary (such one-half amount is currently $150,000) paid over nine months. As additional compensation, the Company granted the Division President a ten-year option to purchase 25,000 shares of common stock at an exercise price of $9.20 per share, pursuant to the Plan. The options vests over three years on the grant date anniversaries. The grant date value of $200,400 is being recognized proportionate to the vesting period. In March 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount is currently $125,000). As of December 31, 2016, two other employees have “at-will” employment agreements with the Company that provide for aggregate cash severance payments of $175,000, payable over twelve months, upon involuntary termination. Board of Directors As of December 31, 2016, and 2015, $357,500 and $200,000, respectively, of director cash compensation was outstanding and included in accrued expenses and other current liabilities in the consolidated balance sheets. Related Party Agreement In March 2015, a 2014 agreement, as amended, between the Company and an affiliate of one of its then directors for consulting services related to the Company’s brtxDISC Program and ThermoStem Program expired. Pursuant to the aggrement, the Company issued 1,725 shares of common stock to one of its then directors. The common stock had a grant date fair value of $15,000 which was recognized immediately and is reflected within consulting expenses within the Company’s consolidated statement of operations.

Stockholders' Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders’ Deficiency	Note 10 – Stockholders’ Deficiency Authorized Capital In December 2014, the Company’s stockholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware effective January 1, 2015 and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000; and (ii) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of preferred stock authorized to be issued by the Company from 1,000,000 to 5,000,000. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split of the Company’s issued and outstanding common stock and a reduction in the number of shares of common stock authorized to be issued by the Company from 200,000,000 to 30,000,000. As of December 31, 2016, the Company was authorized to issue 30,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.01 par value. The holders of the Company’s common stock are entitled to one vote per share. Subject to the rights of holders of preferred stock, if any, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Subject to the rights of holders of preferred stock, if any, upon liquidation, dissolution or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available for distribution. 2010 Equity Participation Plan In September 2015, the Compensation Committee increased the number of shares authorized to be issued pursuant to the Plan from 1,000,000 to 2,000,000, subject to stockholder approval. In November 2015, the Compensation Committee further increased the number of shares authorized to be issued pursuant to the Plan to 2,250,000, subject to stockholder approval. In December 2015, the Company’s stockholders approved an increase in the number of shares of common stock authorized to be issued pursuant to the Plan to 2,250,000. In August 2016 and October 2016, the Compensation Committee and the Company’s stockholders, respectively, approved an increase in the number of shares authorized to be issued pursuant to the Company’s 2010 Equity Participation Plan from 2,250,000 to 4,250,000. Common Stock and Warrant Offerings During the year ended December 31, 2015, the Company issued an aggregate of 395,425 shares of common stock at prices ranging from $4.00 to $7.00 per share to investors for aggregate gross proceeds of $2,033,700 (of such aggregate issuances, 50,000 shares of common stock were issued to the Bermuda Lender for an aggregate gross proceeds of $300,000). In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 259,464 shares of common stock at exercise prices ranging from $5.00 to $15.00 per share of common stock (of such aggregate warrant issuances, the Bermuda Lender was issued a five-year warrant to purchase 12,500 shares of common stock at an exercise price of $15.00 per share with a grant date value of $40,000). The warrants had an aggregate grant date value of $611,730. In connection with the purchase of 125,000 shares of common stock (the “Shares”) and a warrant to purchase 125,000 shares of common stock at an exercise price of $5.00 per share (the “Warrant”) for gross proceeds of $500,000, the Company agreed to cause the appointment and election of the investor to its Board of Directors. In December 2015, the investor was elected as a director of the Company. During the year ended December 31, 2016, the Company issued an aggregate of 956,883 shares of common stock and warrants to purchase an aggregate of 1,801,177 shares of common stock at exercise prices ranging from $4.00 to $5.00 per share to investors for aggregate gross proceeds of $3,498,338. Of the aggregate warrants issued, warrants to purchase 444,444, 400,000 and 956,733 shares of common stock had terms of 0.7, 1.0 and 5.0 years, respectively. The warrants had an aggregate grant date fair value of $2,054,144. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the years ended December 31, 2016 and 2015. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Warrant Exercises During the year ended December 31, 2015, warrants to purchase an aggregate of 75,473 shares of common stock were exercised at a reduced exercise price of $3.50 per share (reduced from exercises prices ranging from $4.00 to $15.00 per share) for aggregate gross proceeds of $264,144. The Company recognized a warrant modification charge of $20,295 during the year ended December 31, 2015 which represents the incremental value of the modified warrant as compared to the original warrant, both valued as of the respective modification dates. During the year ended December 31, 2016, warrants to purchase an aggregate of 60,831 shares of common stock were exercised at a reduced exercise price of $3.50 per share (reduced from exercises prices ranging from $4.00 to $15.00 per share) for aggregate gross proceeds of $212,898. The Company recognized a warrant modification charge of $23,448 during the year ended December 31, 2016, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates . Stock Warrants In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Years Ended December 31, 2016 2015 Risk free interest rate 0.44% - 2.07 % 1.29% - 1.75 % Expected term (years) 0.67 - 5.00 5.00 Expected volatility 124% - 152 % 120% - 122 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the years ended December 31, 2016 and 2015 was approximately $1.18 and $2.72 per share, respectively. See Note 7 – Notes Payable for details associated with the issuance of warrants in connection with note issuances and the exchange of notes payable. See Note 9 – Commitments and Contingencies – Consulting Agreements for details associated with the issuance of warrants as compensation. See Note 10 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings. During the year ended December 31, 2015, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 47,939 shares of common stock from expiration dates ranging from December 31, 2015 to January 23, 2016 to new expiration dates ranging from December 31, 2016 to December 31, 2017 and reduced the exercise price of previously outstanding warrants to purchase an aggregate of 470,085 shares of common stock from exercise prices ranging from $6.00 to $20.00 per share to new exercise prices ranging from $4.00 to $10.00 per share. During year ended December 31, 2015, the Company recognized $77,905 of incremental expense related to the modification of the warrants which is reflected in warrant modification expense in the consolidated statements of operations. During the year ended December 31, 2016, the Company issued an immediately vested five-year warrant to purchase 40,000 shares of common stock at an exercise price of $4.00 per share to a consultant for services rendered. The issuance date fair value of $62,908 was immediately recognized as stock-based compensation expense which is reflected in consulting expense in the consolidated statements of operations. During the year ended December 31, 2016, the Company reduced the exercise price of previously outstanding warrants to purchase an aggregate of 44,166 shares of common stock from exercise prices ranging from $6.00 to $15.00 per share to a new exercise price of $4.00 per share and recognized $5,038 of incremental expense related to the modification of the warrants which is reflected in warrant modification expense in the consolidated statements of operations. The Company recorded stock–based compensation expense of $62,908 and $99,501 during the years ended December 31, 2016 and 2015, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the consolidated statements of operations. As of December 31, 2016, there was no unrecognized stock-based compensation expense related to stock warrants. A summary of the warrant activity during the year ended December 31, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2015 1,066,930 $ 7.56 [1] Issued 1,991,927 4.64 Exercised (60,831 ) 3.50 [2] Forfeited (44,375 ) 4.00 Outstanding, December 31, 2016 2,953,651 $ 5.40 [1] 3.3 $ - Exercisable, December 31, 2016 2,918,651 $ 5.40 3.4 $ - [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2016. [2] During the year ended December 31, 2016, warrants to purchase an aggregate of 60,831 shares of common stock were exercised at a reduced exercise price of $3.50 per share (reduced from exercise prices ranging from $4.00 to $15.00 per share) for aggregate gross proceeds of $212,898. The Company recognized a warrant modification charge of $23,448 during the year ended December 31, 2016, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates. See Note 10 – Stockholders’ Deficiency – Warrant Exercises for additional details. The following table presents information related to stock warrants at December 31, 2016: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 1,554,245 3.4 1,554,245 $5.00 - $5.99 1,169,243 3.4 1,169,243 $6.00 - $7.99 40,000 3.6 40,000 $8.00 - $9.99 2,500 2.9 2,500 $10.00 - $14.99 55,446 3.3 55,446 $15.00 - $19.99 38,559 2.9 38,559 $20.00 - $80.00 58,658 0.7 58,658 Variable [1] 35,000 - - 2,953,651 3.4 2,918,651 [1] A warrant to purchase 35,000 shares of common stock has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2016. Stock Options In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Year Ended December 31, 2016 2015 Risk free interest rate 1.16% - 1.53 % 1.33% - 2.24 % Expected term (years) 5.50 - 10.00 5.00 - 10.00 Expected volatility 124% - 126 % 120% - 123 % Expected dividends 0.00 % 0.00 % The weighted average estimated fair value of the stock options granted during the years ended December 31, 2016 and 2015 was approximately $3.24 and $4.07 per share, respectively. See Note 9 – Commitments and Contingencies for details associated with certain grants of options as compensation to employees, directors and consultants. In September 2015, the Compensation Committee determined that, with respect to all outstanding options granted under the Plan, to the extent not already provided for in the stock option agreement evidencing the option grant, the optionee be given the right to exercise the option on a cashless basis as contemplated by Section 13(b) of the Plan and, other than in the case of the Company’s CEO, in the event of a termination of employment, directorship, consultancy or membership on the Company’s Scientific Advisory Board, to the extent that the options are then exercisable, they shall remain exercisable until twelve months following such termination (unless the stock option agreement evidencing the option grant provides that such options are exercisable until the expiration date of the options), but in no event shall the options be exercisable after the respective expiration dates of the options. In February 2016, the Company granted a ten-year option to a director to purchase 15,000 shares of the Company’s common stock at an exercise price of $3.70. The shares vest ratably over three years on the issuance date anniversaries. The options had an aggregate grant date value of $52,900. In June 2016, the Company issued ten-year options to employees, directors and advisors to purchase an aggregate of 827,000 shares of common stock at an exercise price of $3.73 per share, pursuant to the Plan. The shares vest as follows: (i) 192,333 shares vest immediately, (ii) 384,667 shares vest ratably over two years on the issuance date anniversaries and (iii) 250,000 shares vest ratably over three years on the issuance date anniversaries. The options had an aggregate grant date value of $2,682,800. In August 2016, the Company granted a ten-year option to the Chairman of the Company’s Scientific Advisory Board, to purchase 15,000 shares of the Company’s common stock at an exercise price of $3.10. The shares vest ratably over two years on the issuance date anniversaries. The option had a grant date fair value of $41,000 and will be amortized over the vesting period of the option. The following table presents information related to stock option expense: Weighted Average Remaining For the Year Ended Unrecognized at Amortization December 31, December 31, Period 2016 2015 2016 (Years) Consulting $ 880,288 $ 595,446 $ 902,142 1.4 Research and development 492,061 376,596 902,056 2.0 General and administrative 1,001,445 705,546 1,068,001 1.5 $ 2,373,794 $ 1,677,588 $ 2,872,199 1.6 A summary of the option activity during the year ended December 31, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2015 1,330,450 $ 10.11 Granted 857,000 3.72 Forfeited (18,500 ) 16.41 Outstanding, December 31, 2016 2,168,950 $ 7.53 8.2 $ 3,000 Exercisable, December 31, 2016 1,137,620 $ 9.78 7.6 $ - The following table presents information related to stock options at December 31, 2016: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $3.10 - $3.99 857,000 9.4 192,336 $4.00 - $4.99 15,000 8.9 5,000 $5.00 - $5.99 35,000 7.5 35,000 $6.00 - $6.99 318,750 7.3 213,749 $7.00 - $7.99 507,000 8.6 305,501 $8.00 - $8.99 32,250 8.5 10,750 $9.00 - $9.99 30,000 6.2 13,334 $10.00 - $19.99 198,000 6.5 193,000 $20.00 - $30.00 175,950 5.1 168,950 2,168,950 7.6 1,137,620 Compensatory Common Stock Issuances See Note 9 – Commitments and Contingencies for details associated with certain issuances of common stock as compensation to employees, directors and consultants. During the year ended December 31, 2015, the Company issued an aggregate of 31,473 shares of immediately vested common stock valued at $112,847 to consultants pursuant to consulting agreements for services rendered during the period. During the year ended December 31, 2015, the Company issued 943 shares of common stock valued at $8,481 in satisfaction of previously accrued professional service fees. During the year ended December 31, 2016, the Company issued an aggregate of 54,901 shares of immediately vested common stock valued at $116,958 to consultants pursuant to consulting agreements for services rendered during the period. During the year ended December 31, 2016, the Company issued an aggregate of 13,208 shares of common stock valued at $27,553 in satisfaction of previously accrued consulting services. The following table presents information related to compensatory common stock expense: For The Nine Months Ended Unrecognized at December 31, December 31, 2016 2015 2016 Consulting $ 100,083 $ 168,800 $ - Research and development - 8,847 - $ 100,083 $ 177,647 $ - Return of Shares to Treasury In June 2016, the Company and a consultant agreed that, due to the amount and nature of the services performed, the consultant would return 7,500 shares of common stock to the Company with a fair value of $16,875. Accordingly, the Company recorded the treasury shares at cost with a stock-based compensation credit which is reflected within consulting expense in the consolidated statements of operations. Retirement of Treasury Shares In August 2016, the Company’s Board of Directors made a determination to retire 35,432 shares of treasury stock.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 11 - Subsequent Events Consulting Agreements On March 9, 2017, in consideration of the extension of the term of a consulting agreement, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 25,000 shares of common stock of the Company at an exercise price of $4.00 per share. Concurrently, the Company entered into an exchange agreement with the consultant pursuant to which $30,000 of accrued consulting fees were exchanged for 10,000 shares of common stock of the Company and, in consideration thereof, the Company issued to the consultant an immediately vested five-year warrant for the purchase of 10,000 shares of common stock of the Company at an exercise price of $4.00 per share. Effective March 1, 2017, the Company entered into an exchange agreement with the Chairman of the Company’s Scientific Advisory Board, pursuant to which an aggregate of $175,000 of accrued consulting fees were exchanged for 58,334 shares of common stock of the Company and, in consideration thereof, the Company issued to such person an immediately vested five-year warrant for the purchase of 58,334 shares of common stock of the Company at an exercise price of $4.00 per share. Director Fees Effective March 1, 2017, the Company entered into exchange agreements with four non-employee directors of the Company, pursuant to which an aggregate of $265,000 of accrued director fees were exchanged for an aggregate of 88,334 shares of common stock of the Company and, in consideration thereof, the Company issued to the directors immediately vested five-year warrants for the purchase of an aggregate of 88,334 shares of common stock of the Company at an exercise price of $4.00 per share. Employment Agreements In February 2017 and March 2017, the Company’s Compensation Committee and Board of Directors, respectively, approved performance milestones for the performance-based cash bonuses payable for the year ending December 31, 2017 for certain of the Company’s officers and certain current employees such that an aggregate of up to $402,500 could be earned for such year pursuant to the satisfaction of such goals. Common Stock and Warrant Offerings Subsequent to December 31, 2016, the Company issued an aggregate of 256,668 shares of common stock and five-year immediately vested warrants to purchase an aggregate of 266,668 shares of common stock at an exercise price of $4.00 to investors for aggregate gross proceeds of $770,000. Stock Warrants Subsequent to December 31, 2016, with respect to a warrant held by an investor, the Company agreed that (i) the conditions to the exercisability of the warrant for tranches to purchase an aggregate of 35,000 shares were eliminated, such that the entire warrant to purchase 50,000 shares of common stock was exercisable, and (ii) the exercise price of the warrant was reduced from an exercise price of $30.00 per share to $3.50 per share. Concurrent with the modification of the warrant, the investor exercised the warrant in full for aggregate gross proceeds to the Company of $175,000. Stock Options On February 14, 2017, the Compensation Committee reduced the exercise price of outstanding options for the purchase of an aggregate of 1,219,450 shares of common stock of the Company (with exercise prices ranging between $5.70 and $30.00 per share) to $4.70 per share, which was the closing price for the Company's common stock on February 13, 2017, as reported by the OTCQB. The exercise price reduction related to options held by, among others, the Company's executive officers and directors. Short-Term Advances Subsequent to December 31, 2016, the Company received non-interest bearing advances in the amount of $30,015 from an officer of the Company and repaid an aggregate of $45,015 of non-interest bearing advances from a director of the Company and an officer of the Company. Notes Payable On January 3, 2017, the Company issued a lender a six-month note payable in the principal amount of $242,000, which bears no interest, for cash proceeds of $200,000. The $42,000 difference was recorded as a debt discount and will be amortized over the term of the note. In connection with the issuance of this promissory note, the Company issued the lender an immediately vested five-year warrant to purchase 20,000 shares of common stock an exercise price of $4.00 per share. Subsequent to December 31, 2016, the Company and certain lenders agreed to exchange certain notes payable with an aggregate principal balance of $280,000 and aggregate accrued interest of $7,402 into an aggregate of 95,802 shares of common stock and immediately vested five-year warrants to purchase an aggregate of 95,802 shares of common stock at an exercise price of $4.00 per share. In addition, in consideration of the exchange by one lender, the Company agreed to extend the expiration dates of certain warrants held by the lender for the purchase of an aggregate of 18,000 shares of common stock of the Company at an exercise price of $4.00 per share, from expiration dates ranging from April 27, 2021 to January 31, 2022 to a new expiration date of February 8, 2022. Subsequent to December 31, 2016, the Company elected to convert certain convertible notes with an aggregate principal balance of $45,000 and aggregate accrued interest of $2,277 into an aggregate of 17,854 shares of common stock at conversion prices ranging from $2.51 to $2.77 per share. Subsequent to December 31, 2016, the Company and certain lenders agreed to extend notes payable with an aggregate principal balance of $322,000 from maturity dates ranging between January 2017 to February 2017 to new maturity dates ranging from March 2017 to April 2017. In connection with one of the extensions, the Company issued the lender a five-year, immediately vested warrant to purchase 3,000 shares of common stock at an exercise price of $4.00 per share. Subsequent to December 31, 2016, the Company repaid an aggregate principal amount of $74,000 of notes payable.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements of the Company include the accounts of Cayman and Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. As discussed above, the Company is in the process of dissolving Cayman, which had no material assets, liabilities or operations (other than intercompany balances) and is no longer needed to facilitate certain financings.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations	Concentrations Two pharmaceutical clients comprised substantially all of the Company’s revenue during the year ended December 31, 2015. One license comprised substantially all of the Company’s revenue during the year ended December 31, 2016. See Revenue Recognition – Research and Development Agreements below.
Cash	Cash The Company maintains cash in bank accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts, periodically evaluates the creditworthiness of the financial institutions and has determined the credit exposure to be negligible.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 3 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.
Intangible Assets	Intangible Assets Intangible assets are comprised of trademarks and licenses with original estimated useful lives of 10 and 17.7 years, respectively. Once placed into service, the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight-line basis.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. While the Company’s near term liquidity is tight, historically the Company has been successful in raising capital as needed (although there can be no assurance that the Company will continue to be successful in raising capital as needed). The Company continues to progress its scientific agenda and meet related milestones. Management’s estimate of potential future cash flows still exceeds the carrying value of the long-lived assets. The Company has not identified any impairment losses.
Revenue Recognition	Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. As of December 31, 2015, the Company completed all of its obligations under research and development agreements entered into during 2014. During the years ended December 31, 2016 and 2015, the Company recognized $0 and $609,490, respectively, related to the Company’s research and development agreements. Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after estimating potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. In November 2015, the Company and a stem cell treatment company (“SCTC”) entered into an amendment to a January 27, 2012 license agreement between them. Pursuant to the amendment, effective November 30, 2015, the Company granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States, certain intellectual property related to stem cell disc procedures (that originally was licensed to the Company by the SCTC pursuant to the January 27, 2012 license agreement). In consideration of the sublicense, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. During the years ended December 31, 2016 and 2015, the Company recognized $36,000 and $19,000, respectively, of revenue related to the Company’s sublicense agreements. During the years ended December 31, 2016 and 2015, the Company recognized revenue related to sales of Stem Pearls skincare products of $355 and $425, respectively, with a related cost of sales of $102 and $54, respectively.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of December 31, 2016 and 2015. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2016 2015 Options 2,168,950 1,330,450 Warrants 2,953,651 1,066,930 Convertible notes 211,162 148,708 Total potentially dilutive shares 5,333,763 2,546,088
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Advertising	Advertising Advertising costs are charged to operations as incurred. For the years ended December 31, 2016 and 2015, the Company incurred advertising costs of $17,972 and $23,467, respectively. Advertising expense is reflected in marketing and promotion expenses in the consolidated statements of operations.
Research and Development	Research and Development Research and development expenses are charged to operations as incurred. For the years ended December 31, 2016 and 2015, the Company incurred research and development expenses of $2,883,563 and $2,105,059, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) The carrying amounts of accrued liabilities approximate fair value due to the short-term nature of these instruments. The carrying amounts of our short–term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates, taken together with other features such as concurrent issuance of warrants, are comparable to rates of returns for instruments of similar credit risk.
Convertible Instruments	Convertible Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments (the beneficial conversion feature) based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. To allow entities additional time to implement systems, gather data and resolve implementation questions, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, in August 2015, to defer the effective date of ASU No. 2014-09 for one year, which is fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements or disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and annual and interim periods thereafter, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s financial statement disclosures. In April 2015, the FASB issued ASU No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”, or ASU 2015-03. ASU 2015-03 amends the existing guidance to require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related debt liability instead of as a deferred charge. ASU 2015-03 is effective on a retrospective basis for annual and interim reporting periods beginning after December 15, 2015; earlier adoption is permitted. Additionally, in August 2015 the FASB issued guidance expanding the April 2015 update (ASU No. 2015-15). It states that, given the absence of authoritative guidance within the update, the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset for revolving lines of credit and subsequently amortizing the deferred debt issuance costs ratably over the term of the arrangement, regardless of whether there are any outstanding borrowings on the line of credit. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years, with early adoption permitted for financial statements that have not been previously issued. Full retrospective application is required. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company is currently evaluating ASU 2016-09 and its impact on its consolidated financial statements or disclosures. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”). The amendments in this update clarify the following two aspects to Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. The entity first identifies the promised goods or services in the contract and reduces the cost and complexity. An entity evaluates whether promised goods and services are distinct. Topic 606 includes implementation guidance on determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). ASU 2016-10 is effective for fiscal years beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company is currently evaluating ASU 2016-10 and its impact on its consolidated financial statements or disclosures. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017. The Company will require adoption on a retrospective basis unless it is impracticable to apply, in which case the Company would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its consolidated financial statements or disclosures.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2016 2015 Options 2,168,950 1,330,450 Warrants 2,998,026 1,066,930 Convertible notes 211,162 148,708 Total potentially dilutive shares 5,378,138 2,546,088

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, net	Property and equipment include the following: December 31, 2016 2015 Office equipment $ 2,848 $ 9,494 Medical equipment 446,506 418,280 Furniture and fixtures 121,625 126,150 Computer software and equipment 74,572 85,118 Leasehold improvements 304,661 301,610 950,212 940,652 Less: accumulated depreciation (441,618 ) (297,565 ) Property and equipment, net $ 508,594 $ 643,087

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule Of Intangible Assets By Major Class	Intangible assets consist of the following: Patents and Trademarks Licenses Accumulated Amortization Total Balance as of January 1, 2015 $ 3,676 $ 1,226,500 $ (192,444 ) $ 1,037,732 Additions - 75,000 - 75,000 Amortization expense - - (73,991 ) (73,991 ) Balance as of December 31, 2015 3,676 1,301,500 (266,435 ) 1,038,741 Amortization expense - - (74,896 ) (74,896 ) Balance as of December 31, 2016 $ 3,676 $ 1,301,500 $ (341,331 ) $ 963,845 Weighted average remaining amortization period at December 31, 2016 in years 4.0 12.9
Schedule Of Finite Lived Intangible Assets Amortization Expenses	Amortization of intangible assets consists of the following: Patents and Trademarks Licenses Accumulated Amortization Balance as of January 1, 2015 $ 1,472 $ 190,972 $ 192,444 Amortization expense 368 73,623 73,991 Balance as of December 31, 2015 1,840 264,595 266,435 Amortization expense 368 74,528 74,896 Balance as of December 31, 2016 $ 2,208 $ 339,123 $ 341,331

Accrued Expenses and Other Cu22

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: December 31, 2016 2015 Credit card payable $ 1,778 $ 3,171 Accrued payroll 880,293 1,010,633 Advances from related parties - 87,030 Accrued research and development expenses 406,175 446,175 Accrued general and administrative expenses 233,468 456,182 Deferred rent 52,945 43,604 Accrued expenses, current portion 1,574,659 2,046,795 Accrued expenses, non-current portion 430,000 - Total accrued expenses $ 2,004,659 $ 2,046,795

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the years ended December 31, 2016 and 2015 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, January 1, 2015 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257 ) $ 5,738,239 Issuances 150,000 735,000 [1] 478,018 [1] - 1,363,018 Indebtedness satisfied via settlement - - (5,000 ) - (5,000 ) Exchanges for equity (4,410,937 ) (266,667 ) (877,873 ) - (5,555,477 ) Conversions to equity - (223,333 ) - - (223,333 ) Repayments - - (5,000 ) - (5,000 ) Recognition of debt discount - - - (469,557 )[1] (469,557 ) Accretion of interest expense - - - 85,086 [1] 85,086 Amortization of debt discount - - - 339,443 339,443 Recharacterization of accrued interest as principal - - 44,379 [2] - 44,379 Outstanding, December 31, 2015 $ 150,000 $ 420,000 [3] $ 900,083 $ (158,285 ) $ 1,311,798 Issuances 697,500 530,000 724,500 [1] - 1,952,000 Indebtedness satisfied via settlement - - - - - Exchanges for equity - (235,000 ) (49,018 ) - (284,018 ) Conversion to equity - (325,000 ) - - (325,000 ) Repayments (150,000 ) - (326,500 ) - (476,500 ) Recognition of debt discount - - - (604,067 )[1] (604,067 ) Accretion of interest expense - - - 40,052 [1] 40,052 Amortization of debt discount - - - 542,336 542,336 Outstanding, December 31, 2016 $ 697,500 $ 390,000 [3] $ 1,249,065 $ (179,964 ) $ 2,156,601 Outstanding, December 31, 2015 $ 150,000 $ 420,000 $ 900,083 $ (158,285 ) $ 1,311,798 Less: current portion, December 31, 2015 (150,000 ) (110,000 ) (900,083 ) 150,286 (1,009,797 ) Non-current portion, December 31, 2015 [4] $ - $ 310,000 $ - $ (7,999 ) $ 302,001 Outstanding, December 31, 2016 $ 697,500 $ 390,000 $ 1,249,065 $ (179,964 ) $ 2,156,601 Less: current portion, December 31, 2016 (430,000 ) (345,000 ) (1,236,565 ) 152,720 (1,858,845 ) Non-current portion, December 31, 2016 [4] $ 267,500 $ 45,000 $ 12,500 $ (27,244 ) $ 297,756 [1] During the years ended December 31, 2016 and 2015, notes with an aggregate principal amount of $432,000 and $538,018, respectively, bear no interest and were issued for cash consideration of $374,000 and $450,015, respectively. The difference between the principal amount of the notes and the cash received of $58,000 and $88,003, respectively, was recorded as debt discount and is being accreted to interest expense over the term of the notes. During the year ended December 31, 2015 the Company issued a note payable in the principal amount of $75,000 for a short-term advance from a related party in the amount of $65,000. [2] During the year ended December 31, 2015, in connection with the extension of certain notes payable, an aggregate of $44,379 of accrued interest was added to the aggregate principal balance of the notes. [3] As of December 31, 2016 and 2015, a designated portion of convertible notes with an aggregate principal balance of $390,000 and $420,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $296,250 and $197,500, respectively, of principal into shares of common stock. [4] As of December 31, 2016 and 2015, the Company reclassified principal in the aggregate amount of $297,756 and $302,001, respectively (net of debt discount of $27,244 and $7,999, respectively) and accrued interest in the aggregate amount of $7,681 and $11,011, respectively to notes payable, non-current portion, net of debt discount and accrued interest, non-current portion, respectively, on the consolidated balance sheets related to outstanding notes payable that were converted into or exchanged for shares of common stock and warrants subsequent to December 31, 2016 and 2015, respectively. See Note 11 – Subsequent Events for additional details regarding notes payable.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Domestic and Foreign Components of Loss Before Income Taxes	United States and foreign components of loss before income taxes were as follows: For The Years Ended December 31, 2016 2015 United States $ (8,627,380 ) $ (7,767,924 ) Foreign (8,912 ) (155,556 ) Loss before income taxes $ (8,636,292 ) $ (7,923,480 )
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below: For The Years Ended December 31, 2016 2015 Deferred Tax Assets: Net operating loss carryforward $ 3,495,000 $ 1,181,900 Stock-based compensation 2,868,000 1,976,600 Accruals 237,000 231,100 Research & development tax credits 192,000 139,480 Other 2,000 2,100 Gross deferred tax assets 6,794,000 3,531,180 Deferred Tax Liabilities: Fixed assets (97,000 ) (110,300 ) Intangible assets (18,000 ) (13,400 ) Gross deferred tax liabilities (115,000 ) (123,700 ) Net deferred tax assets 6,679,000 3,407,480 Valuation allowance (6,679,000 ) (3,407,480 ) Deferred tax asset, net of valuation allowance $ - $ - Changes in valuation allowance $ 3,271,520 $ (2,922,620 )
Schedule of Provision for Income Taxes	The income tax provision (benefit) consists of the following: For The Years Ended December 31, 2016 2015 Federal: Current $ - $ - Deferred (2,927,149 ) 2,614,976 State and local: Current - - Deferred (344,371 ) 307,644 (3,271,520 ) 2,922,620 Change in valuation allowance 3,271,520 (2,922,620 ) Income tax provision (benefit) $ - $ -
Schedule of Statutory Federal Income Tax Rate	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: For The Years Ended December 31, 2016 2015 Tax benefit at federal statutory rate (34.0 )% (34.0 )% State income taxes, net of federal benefit (4.0 )% (4.0 )% Permanent differences 0.4 % 0.8 % Research & development tax credits (0.6 )% (0.6 )% Impact of Section 382 limit 0.0 % 76.0 % True-ups and other 0.3 % (0.6 )% Change in valuation allowance 37.9 % (37.6 )% Effective income tax rate 0.0 % 0.0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Lease Future Minimum Payments	Future minimum payments under this operating lease agreement is as follows: For the Years Ending, December 31, Amount 2017 $ 127,948 2018 131,778 2019 148,172 2020 37,315 $ 445,213

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share Based Payment Award Stock Warrants Valuation Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Years Ended December 31, 2016 2015 Risk free interest rate 0.44% - 2.07 % 1.29% - 1.75 % Expected term (years) 0.67 - 5.00 5.00 Expected volatility 124% - 152 % 120% - 122 % Expected dividends 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the year ended December 31, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2015 1,066,930 $ 7.56 [1] Issued 1,991,927 4.64 Exercised (60,831 ) 3.50 [2] Forfeited (44,375 ) 4.00 Outstanding, December 31, 2016 2,953,651 $ 5.40 [1] 3.3 $ - Exercisable, December 31, 2016 2,918,651 $ 5.40 3.4 $ - [1] Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2016. [2] During the year ended December 31, 2016, warrants to purchase an aggregate of 60,831 shares of common stock were exercised at a reduced exercise price of $3.50 per share (reduced from exercise prices ranging from $4.00 to $15.00 per share) for aggregate gross proceeds of $212,898. The Company recognized a warrant modification charge of $23,448 during the year ended December 31, 2016, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates. See Note 10 – Stockholders’ Deficiency – Warrant Exercises for additional details.
Schedule of Stock Warrant	The following table presents information related to stock warrants at December 31, 2016: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $4.00 - $4.99 1,554,245 3.4 1,554,245 $5.00 - $5.99 1,169,243 3.4 1,169,243 $6.00 - $7.99 40,000 3.6 40,000 $8.00 - $9.99 2,500 2.9 2,500 $10.00 - $14.99 55,446 3.3 55,446 $15.00 - $19.99 38,559 2.9 38,559 $20.00 - $80.00 58,658 0.7 58,658 Variable [1] 35,000 - - 2,953,651 3.4 2,918,651 [1] A warrant to purchase 35,000 shares of common stock has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2016.
Schedule of Share Based Payment Award Stock Options Granted Valuation Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Year Ended December 31, 2016 2015 Risk free interest rate 1.16% - 1.53 % 1.33% - 2.24 % Expected term (years) 5.50 - 10.00 5.00 - 10.00 Expected volatility 124% - 126 % 120% - 123 % Expected dividends 0.00 % 0.00 %
Information Related to Stock Option Expense	The following table presents information related to stock option expense: Weighted Average Remaining For the Year Ended Unrecognized at Amortization December 31, December 31, Period 2016 2015 2016 (Years) Consulting $ 880,288 $ 595,446 $ 902,142 1.4 Research and development 492,061 376,596 902,056 2.0 General and administrative 1,001,445 705,546 1,068,001 1.5 $ 2,373,794 $ 1,677,588 $ 2,872,199 1.6
Summary of Stock Option Activity	A summary of the option activity during the year ended December 31, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2015 1,330,450 $ 10.11 Granted 857,000 3.72 Forfeited (18,500 ) 16.41 Outstanding, December 31, 2016 2,168,950 $ 7.53 8.2 $ 3,000 Exercisable, December 31, 2016 1,137,620 $ 9.78 7.6 $ -
Schedule of Stock Option	The following table presents information related to stock options at December 31, 2016: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $3.10 - $3.99 857,000 9.4 192,336 $4.00 - $4.99 15,000 8.9 5,000 $5.00 - $5.99 35,000 7.5 35,000 $6.00 - $6.99 318,750 7.3 213,749 $7.00 - $7.99 507,000 8.6 305,501 $8.00 - $8.99 32,250 8.5 10,750 $9.00 - $9.99 30,000 6.2 13,334 $10.00 - $19.99 198,000 6.5 193,000 $20.00 - $30.00 175,950 5.1 168,950 2,168,950 7.6 1,137,620
Information Related to Common Stock Award Expenses	The following table presents information related to compensatory common stock expense: For The Nine Months Ended Unrecognized at December 31, December 31, 2016 2015 2016 Consulting $ 100,083 $ 168,800 $ - Research and development - 8,847 - $ 100,083 $ 177,647 $ -

Business Organization, Nature27

Business Organization, Nature of Operations (Details Narrative) - shares	Jul. 07, 2015	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1-for-20 reverse split
Changes in capital structure retroactive impact shares	200,000,000
Common stock, shares authorized	30,000,000	30,000,000	30,000,000

Going Concern and Management'28

Going Concern and Management's Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Working capital deficiency	$ 5,783,184
Stockholder's deficiency	(5,000,282)	$ (3,908,463)	$ (6,888,393)
Net loss	8,636,292	7,923,480
Proceeds from equity and debt	945,000	$ 200,000
Amount of debt	325,000
Accrued interest	9,679
Repayment of short term debt	89,000
Repayments of debt	322,000
Past Due [Member]
Notes payable aggregate principal	$ 427,500

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 36,355	$ 628,915
Advertising cost	17,972	23,467
Research and development	2,883,563	2,105,059
Cost of Sales [Member]
Deferred revenue recognized	102	54
Stem Pearls Skincare Products [Member]
Deferred revenue recognized	355	425
Research and Development Agreements [Member]
Revenues	0	609,490
Sublicense Agreement [Member]
Deferred revenue recognized	$ 36,000	$ 19,000
Minimum [Member]
Property plant and equipment estimated useful lives	3 years
Intangible Asset, Useful Life	10 years
Maximum [Member]
Property plant and equipment estimated useful lives	5 years
Intangible Asset, Useful Life	17 years 8 months 12 days

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Total potentially dilutive shares	5,333,763	2,546,088
Options [Member]
Total potentially dilutive shares	2,168,950	1,330,450
Warrants [Member]
Total potentially dilutive shares	2,953,651	1,066,930
Convertible Notes [Member]
Total potentially dilutive shares	211,162	148,708

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciated property and equipment amount	$ 39,476
Depreciation	$ 183,529	$ 139,793

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment, net (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Gross	$ 950,212	$ 940,652
Less: accumulated depreciation	(441,618)	(297,565)
Property and equipment, net	508,594	643,087
Office Equipment [Member]
Property, Plant and Equipment, Gross	2,848	9,494
Medical Equipment [Member]
Property, Plant and Equipment, Gross	446,506	418,280
Furniture And Fixtures [Member]
Property, Plant and Equipment, Gross	121,625	126,150
Computer Software And Equipment [Member]
Property, Plant and Equipment, Gross	74,572	85,118
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	$ 304,661	$ 301,610

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	Mar. 05, 2015	Jan. 27, 2012	Dec. 31, 2016
Milestones payment	$ 75,000
April 2017 [Member]
Milestones payment		$ 150,000	$ 150,000
April 2019 [Member]
Milestones payment		$ 250,000
Through 2029 [Member]
Amortization expenses			$ 75,000

Intangible Assets - Schedule Of

Intangible Assets - Schedule Of Intangible Assets By Major Class (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Finite Lived Intangible Assets, Beginning Balance	$ 1,038,741	$ 1,037,732
Finite Lived Intangible Assets, Additions		75,000
Finite Lived Intangible Assets, Amortization expense	(74,896)	(73,991)
Finite Lived Intangible Assets, Ending Balance	963,845	1,038,741
Patents And Trademarks [Member]
Finite Lived Intangible Assets, Beginning Balance	3,676	3,676
Finite Lived Intangible Assets, Additions
Finite Lived Intangible Assets, Amortization expense
Finite Lived Intangible Assets, Ending Balance	$ 3,676	3,676
Finite Lived Intangible Assets, Weighted Average Amortization Period	4 years
License [Member]
Finite Lived Intangible Assets, Beginning Balance	$ 1,301,500	1,226,500
Finite Lived Intangible Assets, Additions		75,000
Finite Lived Intangible Assets, Amortization expense
Finite Lived Intangible Assets, Ending Balance	$ 1,301,500	1,301,500
Finite Lived Intangible Assets, Weighted Average Amortization Period	12 years 10 months 24 days
Accumulated Amortization [Member]
Finite Lived Intangible Assets, Beginning Balance	$ (266,435)	(192,444)
Finite Lived Intangible Assets, Additions
Finite Lived Intangible Assets, Amortization expense	(74,896)	(73,991)
Finite Lived Intangible Assets, Ending Balance	$ (341,331)	$ (266,435)

Intangible Assets - Schedule 35

Intangible Assets - Schedule Of Finite Lived Intangible Assets Amortization Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Patents And Trademarks [Member]
Beginning Balance	$ 1,840	$ 1,472
Amortization expense	368	368
Ending Balance	2,208	1,840
License [Member]
Beginning Balance	264,595	190,972
Amortization expense	74,528	73,623
Ending Balance	339,123	264,595
Accumulated Amortization [Member]
Beginning Balance	266,435	192,444
Amortization expense	74,896	73,991
Ending Balance	$ 341,331	$ 266,435

Accrued Expenses and Other Cu36

Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Proceeds from related party notes	$ 292,090	$ 564,105
Repayment of advances from officer	364,120	387,075
Debt conversion, original debt, amount		$ 25,000
Debt conversion, converted instrument, shares issued		6,250
Debt conversion, converted instrument, amount	325,000	$ 223,333
Warrants expiration period		5 years
Warrants to purchase common stock		6,250
Exercise price per share		$ 4
Warrants and rights outstanding		$ 11,063
Loss on extinguishment of notes payable, net	(58,787)	(35,677)
Accrued expenses, non-current portion	430,000
Common Stock And Warrants [Member]
Loss on extinguishment of notes payable, net		126
Non-Interest Bearing Advance [Member]
Proceeds from related party notes	292,090	564,105
Repayment of advances from officer	$ 364,120	387,075
Non-Interest Bearing Advance [Member] | Related Party [Member]
Proceeds from convertible debt		65,000
Debt instrument, annual principal payment		$ 75,000

Accrued Expenses and Other Cu37

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Credit card payable	$ 1,778	$ 3,171
Accrued payroll	880,293	1,010,633
Advances from related parties		87,030
Accrued research and development expenses	406,175	446,175
Accrued general and administrative expenses	233,468	456,182
Deferred rent	52,945	43,604
Accrued expenses, current portion	1,574,659	2,046,795
Accrued expenses, non-current portion	430,000
Total accrued expenses	$ 1,574,659	$ 2,046,795

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jul. 15, 2016	Jun. 30, 2016	Mar. 09, 2016	Jul. 30, 2016	Oct. 31, 2015	May 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Proceeds from related party notes							$ 292,090	$ 564,105
Debt conversion, converted instrument, amount							325,000	$ 223,333
Debt conversion, converted instrument, shares issued								6,250
Warrants to purchase common stock								6,250
Common stock an exercise price per share								$ 4
Warrant modification charge							96,634	$ 229,288
Loss on extinguishment of note payables, net							58,787	35,677
Repayments of debt							322,000
Proceeds from single equity or debt financing							945,000	200,000
Amortization of debt discount							542,336	339,443
Debt beneficial conversion feature							231,708	87,788
Directors [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 197,500
Warrant issued term							5 years
Warrants to purchase common stock							8,000
Common stock an exercise price per share							$ 4
Warrant modification charge							$ 55,028
Fair value of warrant							11,959
Amortization of debt discount							$ 7,500
Class of warrant or rights expiration date							Dec. 31, 2018
Debt instrument issued for consideration							$ 190,000
Directors [Member] | Extended Outstanding Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock							844,444
Minimum [Member] | Directors [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Jan. 31, 2017
Common stock an exercise price per share							$ 4.50
Debt instrument interest rate interest							0.00%
Class of warrant or rights expiration date							Nov. 30, 2017
Maximum [Member] | Directors [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Feb. 5, 2017
Common stock an exercise price per share							$ 5
Debt instrument interest rate interest							10.00%
Class of warrant or rights expiration date							Mar. 31, 2018
Convertible Notes [Member] | Issuances [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 530,000	735,000
Debt outstanding principal balance							$ 296,250	$ 272,500
Warrant issued term							5 years	5 years
Warrants to purchase common stock							33,750	30,885
Common stock an exercise price per share							$ 4
Debt instrument interest rate interest							10.00%
Fair value of warrant							$ 53,150	$ 90,018
Amortization of debt discount								10,000
Debt instrument issued for consideration								$ 725,000
Debt instrument conversion period description							September 2016 to August 2017	The convertible notes matured between July 2015 and June 2016
Debt instrument, convertible, conversion price							$ 2
Convertible Notes [Member] | Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 325,000	$ 223,333
Accrued interest							$ 16,751	$ 15,175
Debt conversion, converted instrument, shares issued							137,006	53,595
Debt instrument interest rate interest							10.00%
Debt instrument conversion period description							February 2017 to August 2017
Debt beneficial conversion feature							$ 231,708	$ 87,788
Convertible Notes [Member] | Minimum [Member] | Issuances [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share								$ 5
Debt instrument interest rate interest								1.00%
Conversion price percentage							$ 0.60	$ 0.55
Debt instrument, convertible, conversion price							0.75	2
Convertible Notes [Member] | Minimum [Member] | Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price							1.94	3
Convertible Notes [Member] | Maximum [Member] | Issuances [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share								$ 10
Debt instrument interest rate interest								12.00%
Conversion price percentage							0.62	$ 0.65
Debt instrument, convertible, conversion price							1	3
Convertible Notes [Member] | Maximum [Member] | Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price							$ 3	$ 5.16
Convertible Note One [Member] | Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 235,000	$ 266,667
Debt conversion, converted instrument, amount							298,762
Accrued interest							$ 9,788	$ 12,580
Debt conversion, converted instrument, shares issued							143,102	92,875
Warrant issued term								5 years
Warrants to purchase common stock								39,092
Common stock an exercise price per share								$ 4
Common stock aggregate grant date fair value								$ 288,060
Loss on extinguishment of note payables, net							$ 53,974	8,813
Convertible Note One [Member] | Minimum [Member] | Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price							$ 1.50
Convertible Note One [Member] | Maximum [Member] | Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price							$ 2.10
Other Note [Member] | Issuances [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 724,500	478,018
Proceeds from related party notes								65,000
Aggregate principal amount								$ 75,000
Warrants to purchase common stock							39,000
Common stock an exercise price per share							$ 4
Debt instrument interest rate interest							10.00%	0.00%
Fair value of warrant							$ 61,767
Amortization of debt discount							58,000	$ 78,003
Debt instrument issued for consideration							$ 674,000	$ 400,015
Debt instrument conversion period description							September 2016 to April 2017	October 2015 and December 2015
Other Note [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 49,018	$ 877,873
Debt conversion, converted instrument, amount							$ 53,831
Accrued interest								$ 82,701
Debt conversion, converted instrument, shares issued							23,925	188,632
Warrant issued term								5 years
Warrants to purchase common stock								111,358
Loss on extinguishment of note payables, net							$ 4,813	$ 21,537
Fair value of warrant								$ 982,112
Other Note [Member] | Minimum [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share							$ 1.25	$ 4
Other Note [Member] | Maximum [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share							$ 2.45	$ 15
Other Note One [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 244,000
Debt outstanding principal balance							$ 111,000	$ 735,081
Debt conversion, converted instrument, shares issued							6,000	10,000
Warrant issued term								5 years
Warrants to purchase common stock							8,000	37,500
Common stock an exercise price per share								$ 4
Common stock aggregate grant date fair value							$ 10,000	$ 88,875
Warrant modification charge								10,234
Loss on extinguishment of note payables, net								5,000
Repayments of debt	$ 138,000						96,000	$ 5,000
Amortization of debt discount							13,500
Debt instrument conversion period description								October 2015 to December 2015 to new maturity dates ranging from December 2015 to October 2016.
Debt fee							$ 15,000
Other Note One [Member] | Minimum [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Feb. 5, 2016
Other Note One [Member] | Maximum [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Jul. 15, 2016
Other Note Extended [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument, face amount							$ 567,063
Warrant issued term							5 years
Warrants to purchase common stock							30,000
Common stock an exercise price per share							$ 4
Fair value of warrant							$ 52,800
Amortization of debt discount							$ 13,120
Debt instrument conversion period description							October 2015 to new maturity dates ranging from August 2016 to October 2017
Other Note Extended [Member] | Exchanges And Other [Member] | Additional Warrants [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Oct. 1, 2017
Warrants to purchase common stock							60,215
Common stock an exercise price per share							$ 4
Repayments of debt							$ 92,500
Debt instrument conversion period description							June 2017 to December 2020 had their expiration dates extended to October 2021
Royalty payment term							5 years
Other Note Extended [Member] | Minimum [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument interest rate interest							0.00%
Cosmetic revenue percentage							2.00%
Other Note Extended [Member] | Maximum [Member] | Exchanges And Other [Member]
Debt Instrument [Line Items]
Debt instrument interest rate interest							15.00%
Cosmetic revenue percentage							4.00%
Bermuda Lender [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 500,000
Debt outstanding principal balance						$ 410,937
Debt instrument maturity date						Jun. 30, 2015
Debt conversion, converted instrument, amount						$ 3,733,645
Aggregate principal amount						4,410,937
Accrued interest						$ 69,436
Debt conversion, converted instrument, shares issued						746,730
Warrant issued term						5 years
Warrants to purchase common stock						186,682	40,000
Common stock an exercise price per share						$ 15
Common stock aggregate grant date fair value						$ 672,056
Warrant modification charge							$ 80,000
Loss on extinguishment of note payables, net								$ 5,327
Beneficial ownership percentage							10.00%	10.00%
Bermuda Lender [Member] | Note Payable [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount						500,000
Aggregate principal amount						4,000,000
Bermuda Lender [Member] | Research and Development Agreements [Member]
Debt Instrument [Line Items]
Proceeds from related party notes						$ 316,297
Affiliate Bermuda Lender [Member]
Debt Instrument [Line Items]
Proceeds from related party notes					$ 150,000
Affiliate Bermuda Lender [Member] | Two Month Note [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 150,000
Debt instrument maturity date								Mar. 9, 2016
Warrants to purchase common stock			239,182
Warrant modification charge			$ 98,739
Debt instrument interest rate interest					10.00%
Repayments of debt				$ 150,000
Affiliate Bermuda Lender [Member] | Two Month Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share			$ 4
Affiliate Bermuda Lender [Member] | Two Month Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share			$ 15
Tuxis Trust [Member]
Debt Instrument [Line Items]
Proceeds from related party notes		$ 500,000
Warrants to purchase common stock		40,000
Common stock an exercise price per share		$ 4
Debt instrument interest rate interest		10.00%
Proceeds from single equity or debt financing		$ 10,000,000
Fair value of warrant		$ 55,659
Lender [Member] | Other Note One [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock								35,215
Lender [Member] | Other Note One [Member] | Minimum [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share								$ 10
Lender [Member] | Other Note One [Member] | Maximum [Member]
Debt Instrument [Line Items]
Common stock an exercise price per share								$ 4

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015
Outstanding		$ 1,311,798		$ 5,738,239
Issuance		1,952,000		1,363,018
Indebtedness satisfied via settlement				(5,000)
Exchanges to equity		(284,018)		(5,555,477)
Conversion to equity		(325,000)		(223,333)
Repayments		(476,500)		(5,000)
Recognition of debt discount		(604,067)		(469,557)
Accretion of interest expense		40,052		85,086
Amortization of debt discount		542,336		339,443
Recharacterization of accrued interest as principal				44,379
Outstanding		2,156,601		1,311,798
Less: current portion		(1,858,845)		(1,009,797)
Non-current portion		297,756		302,001
Debt Discount [Member]
Outstanding		(158,285)		(113,257)
Issuance
Indebtedness satisfied via settlement
Exchanges to equity
Conversion to equity
Repayments
Recognition of debt discount	[1]	(604,067)		(469,557)
Accretion of interest expense	[1]	40,052		85,086
Amortization of debt discount		542,336		339,443
Recharacterization of accrued interest as principal
Outstanding		(179,964)		(158,285)
Less: current portion		152,720		(150,286)
Non-current portion	[2]	(27,244)		(7,999)
Convertible Notes [Member]
Outstanding		420,000	[3]	175,000
Issuance		530,000		735,000	[1]
Indebtedness satisfied via settlement
Exchanges to equity		(235,000)		(266,667)
Conversion to equity		(325,000)		(223,333)
Repayments
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Recharacterization of accrued interest as principal
Outstanding		390,000	[4]	420,000	[3]
Less: current portion		(345,000)		(110,000)
Non-current portion	[2]	45,000		310,000
Other Notes [Member]
Outstanding		900,083		1,265,559
Issuance		724,500	[5]	478,018	[1]
Indebtedness satisfied via settlement				(5,000)
Exchanges to equity		(49,018)		(877,873)
Conversion to equity
Repayments		(326,500)		(5,000)
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Recharacterization of accrued interest as principal	[6]			44,379
Outstanding		1,249,065		900,083
Less: current portion		(1,236,565)		(900,083)
Non-current portion	[2]	12,500
Related Party Notes [Member]
Outstanding		150,000		4,410,937
Issuance		697,500		150,000
Indebtedness satisfied via settlement
Exchanges to equity				(4,410,937)
Conversion to equity
Repayments		(150,000)
Recognition of debt discount
Accretion of interest expense
Amortization of debt discount
Recharacterization of accrued interest as principal
Outstanding		697,500		150,000
Less: current portion		(430,000)		(150,000)
Non-current portion	[2]	$ 267,500
[1]	During the years ended December 31, 2016 and 2015, notes with an aggregate principal amount of $432,000 and $538,018, respectively, bear no interest and were issued for cash consideration of $374,000 and $450,015, respectively. The difference between the principal amount of the notes and the cash received of $58,000 and $88,003, respectively, was recorded as debt discount and is being accreted to interest expense over the term of the notes. During the year ended December 31, 2015 the Company issued a note payable in the principal amount of $75,000 for a short-term advance from a related party in the amount of $65,000.
[2]	As of December 31, 2016 and 2015, the Company reclassified principal in the aggregate amount of $297,756 and $302,001, respectively (net of debt discount of $27,244 and $7,999, respectively) and accrued interest in the aggregate amount of $7,681 and $11,011, respectively to notes payable, non-current portion, net of debt discount and accrued interest, non-current portion, respectively, on the consolidated balance sheets related to outstanding notes payable that were converted into or exchanged for shares of common stock and warrants subsequent to December 31, 2016 and 2015, respectively. See Note 11 - Subsequent Events for additional details regarding notes payable.
[3]	As of December 31, 2016 and 2015, a designated portion of convertible notes with an aggregate principal balance of $390,000 and $420,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $296,250 and $197,500, respectively, of principal into shares of common stock.
[4]	As of September 30, 2016 and December 31, 2015, convertible notes with an aggregate principal balance of $155,000 and $420,000, respectively, were convertible into shares of common stock at the election of the Company near maturity. In the event the Company exercised or exercises that conversion right on a designated portion of such principal balance, the holder had or has the right to accelerate the conversion of up to $80,000 and $197,500, respectively, of principal into shares of common stock.
[5]	During the nine months ended September 30, 2016, the Company issued a lender a note payable in the principal amount of $242,000 for cash proceeds of $200,000.
[6]	During the year ended December 31, 2015, in connection with the extension of certain notes payable, an aggregate of $44,379 of accrued interest was added to the aggregate principal balance of the notes.

Notes Payable - Schedule of N40

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Debt discount		$ 542,336	$ 339,443
Related party short-term advance		292,090	564,105
Accrued interest		7,681	11,011
Note Payable		297,756	302,001
Debt discount		27,244	7,999
Convertible Notes [Member]
Debt discount
Note Payable	[1]	45,000	310,000
Notes Payable [Member]
Aggregate principal amount		432,000	538,018
Cash consideration		374,000	450,015
Debt discount		58,000	88,003
Note payable principal amount			75,000
Related party short-term advance			65,000
Notes Payable Two [Member]
Accrued interest			44,379
Notes Payable Three [Member] | Convertible Notes [Member]
Aggregate principal amount		390,000	420,000
Cash consideration		$ 296,250	$ 197,500
[1]	As of December 31, 2016 and 2015, the Company reclassified principal in the aggregate amount of $297,756 and $302,001, respectively (net of debt discount of $27,244 and $7,999, respectively) and accrued interest in the aggregate amount of $7,681 and $11,011, respectively to notes payable, non-current portion, net of debt discount and accrued interest, non-current portion, respectively, on the consolidated balance sheets related to outstanding notes payable that were converted into or exchanged for shares of common stock and warrants subsequent to December 31, 2016 and 2015, respectively. See Note 11 - Subsequent Events for additional details regarding notes payable.

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Aug. 31, 2015	Jul. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal and state net operating losses			$ 9,200,000	$ 3,100,000
Income tax expire year description			expire from 2029 to 2036
Maximum ownership changes percentage			50.00%
Net operating loss federal not being realizable	$ 15,500,000	$ 5,700,000
Net operating loss deferred tax assets	$ 5,900,000	$ 2,200,000	$ 3,495,000	$ 1,181,900

Income Taxes - Schedule of Dome

Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
United States	$ (8,627,380)	$ (7,767,924)
Foreign	(8,912)	(155,556)
Loss before income taxes	$ (8,636,292)	$ (7,923,480)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilites (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Aug. 31, 2015	Jul. 31, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 3,495,000	$ 1,181,900	$ 5,900,000	$ 2,200,000
Stock-based compensation	2,868,000	1,976,600
Accruals	237,000	231,100
Research & development tax credits	192,000	139,480
Other	2,000	2,100
Gross deferred tax assets	6,794,000	3,531,180
Fixed assets	(97,000)	(110,300)
Intangible assets	(18,000)	(13,400)
Gross deferred tax liabilities	(115,000)	(123,700)
Net deferred tax assets	6,679,000	3,407,480
Valuation allowance	(6,679,000)	(3,407,480)
Deferred tax asset, net of valuation allowance
Changes in valuation allowance	$ 3,271,520	$ (2,922,620)

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal, Current
Federal, Deferred	(2,927,149)	2,614,976
State and local, Current
State and local, Deferred	(344,371)	307,644
Income tax provision (benefit) before change in valuation allowance	(3,271,520)	2,922,620
Change in valuation allowance	3,271,520	(2,922,620)
Income tax provision (benefit)

Income Taxes - Schedule of Stat

Income Taxes - Schedule of Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(4.00%)	(4.00%)
Permanent differences	0.40%	0.80%
Research & development tax credits	(0.60%)	(0.60%)
Impact of Section 382 limit	0.00%	76.00%
True-ups and other	0.30%	(0.60%)
Change in valuation allowance	37.90%	(37.60%)
Effective income tax rate	0.00%	0.00%

Commitments and Contingencies46

Commitments and Contingencies (Details Narrative)	1 Months Ended		12 Months Ended
	Mar. 31, 2015USD ($)shares	Feb. 28, 2015USD ($)$ / sharesshares	Dec. 31, 2016USD ($)ft²$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares
Security deposit			$ 45,900	$ 45,900
Rent expense			124,038	$ 141,131
Warrants to purchase common stock | shares				6,250
Exercise price per share | $ / shares				$ 4
Research and development expense			2,883,563	$ 2,105,059
Operating expenses			7,833,510	7,537,773
Employee-related liabilities			$ 602,221	797,576
Stock-based compensation, stock option granted | shares			857,000
Common stock exercise price | $ / shares			$ 3.72
Chief Executive Officer [Member]
Cash bonuses			$ 96,000
Bonus payments			$ 49,691
Chief Executive Officer [Member] | Effective From January 1 2015 [Member]
Salary reduced	$ 7,200
Division President [Member]
Severance costs		$ 150,000
Stock-based compensation, stock option granted | shares		25,000
Common stock exercise price | $ / shares		$ 9.20
Share based compensation arrangement by share based payment award options grant intrinsic value		$ 200,400
Vice President of Research and Development [Member]
Severance costs	$ 125,000
Directors [Member]
Warrants to purchase common stock | shares			8,000
Exercise price per share | $ / shares			$ 4
Board of Directors [Member]
Accounts payable and accrued liabilities, total			$ 357,500	$ 200,000
Settlement Agreement [Member]
Number of common stock issued | shares				4,230
Warrants to purchase common stock | shares				30,000
Proceeds from issuance of warrants				$ 152,000
Warrant term				5 years
Related Party Agreement[Member]
Stock-based compensation, stock option granted | shares	1,725
Grant date value	$ 15,000
Minimum [Member] | Directors [Member]
Exercise price per share | $ / shares			$ 4.50
Minimum [Member] | Settlement Agreement [Member]
Exercise price per share | $ / shares				$ 7.60
Maximum [Member] | Directors [Member]
Exercise price per share | $ / shares			$ 5
Maximum [Member] | Settlement Agreement [Member]
Exercise price per share | $ / shares				$ 12
Melville Lease [Member]
Land subject to ground leases | ft²			6,800
Lease expiration term			2020-03
Security deposit			$ 45,900	$ 45,900
Received rent payments			20,912
Melville Lease [Member] | Minimum [Member]
Accrued rent			132,600
Melville Lease [Member] | Maximum [Member]
Accrued rent			149,260
Research Agreements [Member]
Research and development expense			112,000	103,000
Business Advisory Services [Member]
Consulting expense			$ 180,000	180,000
Business Advisory Services [Member] | Extension 1 [Member]
Warrants to purchase common stock | shares			10,000
Exercise price per share | $ / shares			$ 12
Warrant term			5 years
Additional monthly fee for services rendered			$ 15,000
Business Advisory Services [Member] | Extension 2 [Member]
Warrants to purchase common stock | shares			10,000
Proceeds from issuance of warrants			$ 74,923
Exercise price per share | $ / shares			$ 10
Warrant term			5 years
Employment Agreements [Member]
Cash bonuses			$ 95,041
Bonus payments			50,531
Employment Agreements [Member] | Chief Executive Officer [Member]
Deferred compensation arrangement with individual, description	The CEO is entitled to receive a salary of $400,000 per annum and, effective January 1, 2015, the CEO’s annual car allowance was reduced to $7,200 from $14,400. Pursuant to the employment agreement, the CEO was entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and is entitled to receive an annual bonus for each of 2016 and 2017 of up to 50% of his annual base salary in the event certain performance goals, as determined by the Compensation Committee of the Board of Directors of the Company(the “Compensation Committee”), are satisfied.
Salary amount	$ 400,000
Labor and related expense, total	$ 14,400
Deferred compensation amount			100,000
Operating expenses			$ 407,200	$ 407,200
Employment Agreements [Member] | Chief Executive Officer [Member] | February 2017[Member]
Deferred compensation arrangement with individual, description			In February 2017, the Compensation Committee and the CEO agreed to amend the CEO’s 2016 annual bonus such that (i) the total bonus that could be earned would be equal to 40% of the CEO’s 2016 annual salary and (ii) the CEO would have until July 31, 2017 to satisfy certain performance goals related to his 2016 bonus.
Employment Agreements [Member] | Two Other Employees [Member]
Severance costs			$ 175,000
Employment Agreements [Member] | Maximum [Member]
Cash bonuses			225,750
Employment Agreements [Member] | Maximum [Member] | March 2017[Member]
Cash bonuses			162,000
Chief Executive Officer Employment Agreements [Member]
Deferred compensation amount			$ 300,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Operating Lease Future Minimum Payments (Details)	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 127,948
2,018	131,778
2,019	148,172
2,020	37,315
Total	$ 445,213

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	Jul. 07, 2015	Aug. 31, 2016	Jun. 30, 2016	Feb. 29, 2016	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2016	Nov. 30, 2015	Sep. 30, 2015	May 31, 2015	Dec. 31, 2014
Common stock, shares authorized	30,000,000				30,000,000	30,000,000
Preferred stock, shares authorized					5,000,000	5,000,000
Reverse stock split	1-for-20 reverse split
Common stock, par value					$ 0.001	$ 0.001
Preferred stock, par value					$ 0.01	$ 0.01
Warrants to purchase common stock						6,250
Exercise price per share						$ 4
Warrant modification charge					$ 96,634	$ 229,288
Stock based compensation expenses					$ 2,536,785	1,954,736
Purchase of shares of common stock					857,000
Number of common stock shares issued for services					$ 27,553	8,481
Retirement of treasury shares					$ 48,875
Board of Directors [Member]
Retirement of treasury shares		$ 35,432
Common Stock [Member]
Number of common stock issued					956,833	395,425
Warrants to purchase common stock						125,000
Warrant modification charge
Number of common stock shares issued for services, shares					13,208	943
Number of common stock shares issued for services					$ 13	$ 1
Warrant [Member]
Warrants to purchase common stock						125,000
Exercise price per share						$ 5
Gross proceeds from warrants						$ 500,000
Stock Offering One [Member]
Warrant term					8 months 12 days
Warrants to purchase common stock					444,444
Stock Offering Two [Member]
Warrant term					1 year
Warrants to purchase common stock					400,000
Stock Offering Three [Member]
Warrant term					5 years
Warrants to purchase common stock					956,733
Bermuda Lender [Member]
Warrants to purchase common stock					40,000					186,682
Exercise price per share										$ 15
Warrant modification charge					$ 80,000
Consultant [Member]
Number of common stock shares issued for services, shares					54,901	31,473
Number of common stock shares issued for services					$ 116,958	$ 112,847
Purchase of treasury shares			7,500
Purchase of treasury shares fair value			$ 16,875
Consultant One [Member]
Number of common stock shares issued for services, shares					13,208	943
Number of common stock shares issued for services					$ 27,553	$ 8,481
Common Stock and Warrant Offerings [Member]
Number of common stock issued					956,883	395,425
Gross proceeds from common stock						$ 2,033,700
Warrant term						5 years
Warrants to purchase common stock					1,801,177	259,464
Warrants grant date fair value					$ 2,054,144	$ 611,730
Gross proceeds from warrants					$ 3,498,338
Common Stock and Warrant Offerings [Member] | Bermuda Lender [Member]
Number of common stock issued						50,000
Shares issued price per share						$ 15
Gross proceeds from common stock						$ 300,000
Warrant term						5 years
Warrants to purchase common stock						12,500
Warrants grant date fair value						$ 40,000
Warrant Exercises [Member]
Warrants to purchase common stock					60,831	75,473
Exercise price per share					$ 3.50	$ 3.50
Gross proceeds from warrants					$ 212,898	$ 264,144
Warrant modification charge					$ 23,448	$ 20,295
Stock Warrants [Member]
Warrants to purchase common stock					470,085	47,939
Warrant modification charge						$ 77,905
Weighted average estimated fair value of the warrants granted					$ 1.18	$ 2.72
Warrrants expiration date description						expiration dates ranging from December 31, 2015 to January 23, 2016 to new expiration dates ranging from December 31, 2016 to December 31, 2017
Stock based compensation expenses					$ 62,908	$ 99,501
Stock Warrants [Member] | Consultant [Member]
Warrants to purchase common stock					40,000
Exercise price per share					$ 4
Stock based compensation expenses					$ 62,908
Stock Warrants One [Member]
Warrants to purchase common stock					44,166
Exercise price per share					$ 4
Warrant modification charge					$ 5,038
Stock Options [Member]
Option exercise price			$ 3.73
Common stock an exercise price per share			$ 192,333
2010 Equity Participation Plan [Member]
Number of shares authorized						2,250,000		2,250,000
Stock Options [Member]
Weighted average estimated fair value of the warrants granted					$ 3.24
Purchase of shares of common stock		15,000	827,000	15,000
Option exercise price		$ 3.10		$ 3.70
Aggregate grant date value		$ 41,000		$ 52,900
Stock options term		10 years	10 years	10 years
Shares vested term		2 years	3 years	3 years
Number of shares vested			2,682,800
Stock Options [Member]
Weighted average estimated fair value of the warrants granted						$ 4.07
Over Two Years [Member] | Stock Options [Member]
Number of shares vested			384,667
Over Three Years [Member] | Stock Options [Member]
Number of shares vested			250,000
Minimum [Member]
Common stock, shares authorized	200,000,000										100,000,000
Preferred stock, shares authorized											1,000,000
Minimum [Member] | Common Stock and Warrant Offerings [Member]
Shares issued price per share						4
Exercise price per share					$ 4	$ 5
Minimum [Member] | Warrant And Option Valuation [Member]
Estimated forfeitures related to option grants at an annual rate					0.00%	0.00%
Minimum [Member] | Warrant Exercises [Member]
Exercise price per share					$ 4	$ 4
Minimum [Member] | Stock Warrants [Member]
Exercise price per share					4	6
Minimum [Member] | Stock Warrants One [Member]
Exercise price per share					6
Minimum [Member] | 2010 Equity Participation Plan [Member]
Common stock, shares authorized		2,250,000					2,250,000		1,000,000
Maximum [Member]
Common stock, shares authorized	30,000,000										200,000,000
Preferred stock, shares authorized											5,000,000
Maximum [Member] | Common Stock and Warrant Offerings [Member]
Shares issued price per share						7
Exercise price per share					$ 5	$ 15
Maximum [Member] | Warrant And Option Valuation [Member]
Estimated forfeitures related to option grants at an annual rate					5.00%	5.00%
Maximum [Member] | Warrant Exercises [Member]
Exercise price per share					$ 15	$ 15
Maximum [Member] | Stock Warrants [Member]
Exercise price per share					10	$ 20
Maximum [Member] | Stock Warrants One [Member]
Exercise price per share					$ 15
Maximum [Member] | 2010 Equity Participation Plan [Member]
Common stock, shares authorized		4,250,000					4,250,000		2,000,000

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Share based Payment Award Warrants Valuation Assumptions (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Expected term (years)		5 years
Expected dividends	0.00%	0.00%
Minimum [Member]
Risk free interest rate	0.44%	1.75%
Expected term (years)	8 months 1 day
Expected volatility	124.00%	122.00%
Maximum [Member]
Risk free interest rate	2.07%	1.29%
Expected term (years)	5 years
Expected volatility	152.00%	120.00%

Stockholders' Deficiency - Summ

Stockholders' Deficiency - Summary of Warrant Activity (Details)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Number of Warrants Exercisable, Balance | shares	1,137,620
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 10.11
Weighted Average Exercise Price Outstanding, Issued	3.72
Weighted Average Exercise Price Outstanding, Forfeited	16.41
Weighted Average Exercise Price Outstanding, Ending Balance	7.53
Weighted Average Exercise Price Exercisable, Balance	$ 9.78
Weighted Average Remaining Life In Years Outstanding	8 years 2 months 12 days
Weighted Average Remaining Life In Years Exercisable	7 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding | $	$ 3,000
Aggregate Intrinsic Value, Exercisable | $
Warrant [Member]
Number of Warrants Outstanding, Beginning Balance | shares	1,066,930
Number of Warrants Outstanding, Issued | shares	1,991,927
Number of Warrants Outstanding, Exercised | shares	(60,831)
Number of Warrants Outstanding, Forfeited | shares	(44,375)
Number of Warrants Outstanding, Ending Balance | shares	2,953,651
Number of Warrants Exercisable, Balance | shares	2,918,651
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 7.56	[1]
Weighted Average Exercise Price Outstanding, Issued	4.64
Weighted Average Exercise Price Outstanding, Exercised	3.50	[2]
Weighted Average Exercise Price Outstanding, Forfeited	4
Weighted Average Exercise Price Outstanding, Ending Balance	5.40	[1]
Weighted Average Exercise Price Exercisable, Balance	$ 5.40
Weighted Average Remaining Life In Years Outstanding	3 years 3 months 18 days
Weighted Average Remaining Life In Years Exercisable	3 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $
[1]	Excludes the impact of a warrant to purchase 35,000 shares of common stock that has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2016.
[2]	During the year ended December 31, 2016, warrants to purchase an aggregate of 60,831 shares of common stock were exercised at a reduced exercise price of $3.50 per share (reduced from exercise prices ranging from $4.00 to $15.00 per share) for aggregate gross proceeds of $212,898. The Company recognized a warrant modification charge of $23,448 during the year ended December 31, 2016, which represents the incremental value of the modified warrants as compared to the original warrants, both valued as of the respective modification dates. See Note 10 - Stockholders' Deficiency - Warrant Exercises for additional details.

Stockholders' Deficiency - Su51

Stockholders' Deficiency - Summary of Warrant Activity (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Exercise price per share		$ 4
Proceeds from warrant exercise	$ 212,898	$ 264,144
Warrant modification charge	$ 96,634	$ 229,288
Warrant Exercises [Member]
Warrants to purchase shares of common stock	60,831
Exercise price per share	$ 3.50	$ 3.50
Proceeds from warrant exercise	$ 212,898
Warrant modification charge	$ 23,448	$ 20,295
Warrant Exercises [Member] | Minimum [Member]
Exercise price per share	$ 4	$ 4
Warrant Exercises [Member] | Maximum [Member]
Exercise price per share	$ 15	$ 15
Warrant [Member]
Warrants to purchase shares of common stock	35,000
Exercise price per share	$ 30

Stockholders' Deficiency - Sc52

Stockholders' Deficiency - Schedule of Stock Warrant (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,953,651
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	2,918,651
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,554,245
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	1,554,245
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,169,243
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	1,169,243
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	2,500
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	55,446
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	55,446
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	38,559
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	38,559
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	58,658
Warrants Exercisable, Weighted Average Remaining Life In Years	8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	58,658
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	35,000	[1]
Warrants Exercisable, Weighted Average Remaining Life In Years	0 years	[1]
Warrants Exercisable, Exercisable Number of Warrants		[1]
Minimum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Minimum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5
Minimum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	6
Minimum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	8
Minimum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	10
Minimum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	15
Minimum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	80
Maximum [Member] | Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	4.99
Maximum [Member] | Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	5.99
Maximum [Member] | Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	7.99
Maximum [Member] | Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	9.99
Maximum [Member] | Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	14.99
Maximum [Member] | Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	19.99
Maximum [Member] | Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 20
[1]	A warrant to purchase 35,000 shares of common stock has an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability is subject to satisfaction of certain performance criteria which did not occur during the year ended December 31, 2016.

Stockholders' Deficiency - Sc53

Stockholders' Deficiency - Schedule of Stock Warrant (Details) (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Exercise price per share		$ 4
Warrant [Member]
Warrants to purchase shares of common stock	35,000
Exercise price per share	$ 30

Stockholders' Deficiency - Sc54

Stockholders' Deficiency - Schedule of Share based Payment Award Stock Option Granted Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock Options [Member]
Expected dividends	0.00%
Stock Options [Member]
Expected dividends		0.00%
Minimum [Member] | Options [Member]
Risk free interest rate	1.16%	1.33%
Expected term (years)	5 years 6 months	5 years
Expected volatility	124.00%	120.00%
Maximum [Member] | Options [Member]
Risk free interest rate	1.53%	2.24%
Expected term (years)	10 years	10 years
Expected volatility	126.00%	123.00%

Stockholders' Deficiency - Info

Stockholders' Deficiency - Information Related to Stock Option Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options [Member]
Unrecognized expense	$ 2,872,199
Option [Member]
Stock-based compensation expense	$ 2,373,794	$ 1,677,588
Weighted Average Remaining Amortization Period	1 year 7 months 6 days
Consulting Expense [Member] | Options [Member]
Stock-based compensation expense	$ 880,288	595,446
Unrecognized expense	$ 902,142
Weighted Average Remaining Amortization Period	1 year 4 months 24 days
Research and Development Expense [Member] | Options [Member]
Stock-based compensation expense	$ 492,061	376,596
Unrecognized expense	$ 902,056
Weighted Average Remaining Amortization Period	2 years
General and Administrative Expense [Member] | Options [Member]
Stock-based compensation expense	$ 1,001,445	$ 705,546
Unrecognized expense	$ 1,068,001
Weighted Average Remaining Amortization Period	1 year 6 months

Stockholders' Deficiency - Su56

Stockholders' Deficiency - Summary of Stock Option (Details)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Equity [Abstract]
Number of Options, Outstanding, beginning | shares	1,330,450
Number of Options, Granted | shares	857,000
Number of Options, Forfeited | shares	(18,500)
Number of Options, Outstanding at ending | shares	2,168,950
Number of Options, Exercisable | shares	1,137,620
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 10.11
Weighted Average Exercise Price, Granted | $ / shares	3.72
Weighted Average Exercise Price, Forfeited | $ / shares	16.41
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	7.53
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 9.78
Weighted Average Remaining Life In Years Outstanding	8 years 2 months 12 days
Weighted Average Remaining Life In Years Exercisable	7 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding | $	$ 3,000
Aggregate Intrinsic Value, Exercisable | $

Stockholders' Deficiency - Sc57

Stockholders' Deficiency - Schedule of Stock Options (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	2,168,950
Options Exercisable, Weighted Average Remaining Life In Years	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	1,137,620
Exercise Price One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	857,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	192,336
Exercise Price One [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.10
Exercise Price One [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	15,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	5,000
Exercise Price Two [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Two [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 6 months
Options Exercisable, Exercisable Number of Options	35,000
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	318,750
Options Exercisable, Weighted Average Remaining Life In Years	7 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	213,749
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 6.99
Exercise Price Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	507,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	305,501
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 7
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 7.99
Exercise Price Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	32,250
Options Exercisable, Weighted Average Remaining Life In Years	8 years 6 months
Options Exercisable, Exercisable Number of Options	10,750
Exercise Price Six [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 8
Exercise Price Six [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 8.99
Exercise Price Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	30,000
Options Exercisable, Weighted Average Remaining Life In Years	6 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	13,334
Exercise Price Seven [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 9
Exercise Price Seven [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 9.99
Exercise Price Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	198,000
Options Exercisable, Weighted Average Remaining Life In Years	6 years 6 months
Options Exercisable, Exercisable Number of Options	193,000
Exercise Price Eight [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price Eight [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 19.99
Exercise Price Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	175,950
Options Exercisable, Weighted Average Remaining Life In Years	5 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	168,950
Exercise Price Nine [Member] | Minimum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 20
Exercise Price Nine [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price | $ / shares	$ 30

Stockholders' Deficiency - In58

Stockholders' Deficiency - Information Related to Common Stock Award Expense (Detail) - Common Stock Award [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation expense	$ 100,083	$ 177,647
Unrecognized expense
Consulting Expense [Member]
Stock-based compensation expense	100,083	168,800
Unrecognized expense
Research and Development Expense [Member]
Stock-based compensation expense		$ 8,847
Unrecognized expense

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 09, 2017	Mar. 01, 2017	Feb. 14, 2017	Jan. 03, 2017	Dec. 31, 2016	Dec. 31, 2015
Warrant exercise price						$ 4
Exercise price of outstanding option to purchase					2,168,950
Proceeds from related party notes					$ 292,090	$ 564,105
Repayments of related party					364,120	387,075
Proceeds from note payable					1,894,000	1,210,015
Amortization of debt discount					542,336	339,443
Repayment of note payable					476,500	5,000
Notes Payable [Member]
Proceeds from related party notes						65,000
Aggregate principal amount					432,000	538,018
Amortization of debt discount					$ 58,000	$ 88,003
Consultant [Member]
Number of common stock shares exchanged					54,901	31,473
Subsequent Event [Member]
Accrued interest					$ 2,277
Convertible notes payable					$ 45,000
Number of common stock shares convertible					17,854
Maturity date description					maturity dates ranging between January 2017 to February 2017 to new maturity dates ranging from March 2017 to April 2017.
Repayment of note payable					$ 74,000
Subsequent Event [Member] | Extend Notes Payable [Member]
Aggregate principal amount					$ 322,000
Subsequent Event [Member] | Notes Payable [Member]
Warrant to purchase common stock issued in period					3,000
Warrant exercise price					$ 4
Subsequent Event [Member] | Maximum [Member]
Conversion price per share					2.77
Subsequent Event [Member] | Minimum [Member]
Conversion price per share					$ 2.51
Subsequent Event [Member] | Stock Warrants [Member]
Warrant to purchase common stock issued in period					50,000
Gross proceeds from warrant					$ 175,000
Warrant tranches to purchase of shares					35,000
Subsequent Event [Member] | Stock Warrants [Member] | Maximum [Member]
Warrant exercise price					$ 30
Subsequent Event [Member] | Stock Warrants [Member] | Minimum [Member]
Warrant exercise price					$ 3.50
Subsequent Event [Member] | Stock Options [Member]
Exercise price of outstanding option to purchase			1,219,450
Exercise price range, lower range limit			$ 5.70
Exercise price range, upper range limit			30
Closing price per share			$ 4.70
Subsequent Event [Member] | Common Stock and Warrant Offerings [Member]
Number of common stock issued					256,668
Subsequent Event [Member] | Investors [Member] | Common Stock and Warrant Offerings [Member]
Warrant vested term					5 years
Warrant to purchase common stock issued in period					266,668
Warrant exercise price					$ 4
Gross proceeds from warrant					$ 770,000
Subsequent Event [Member] | Officer [Member]
Proceeds from related party notes					30,015
Subsequent Event [Member] | Director and Officer [Member]
Repayments of related party					$ 45,015
Subsequent Event [Member] | Lender [Member]
Warrant vested term				5 years	5 years
Warrant to purchase common stock issued in period				20,000	95,802
Warrant exercise price				$ 4	$ 4
Number of common stock issued					95,802
Aggregate principal amount				$ 242,000	$ 280,000
Proceeds from note payable				200,000
Amortization of debt discount				$ 42,000
Accrued interest					$ 7,402
Subsequent Event [Member] | Lender One [Member]
Warrant to purchase common stock issued in period					18,000
Warrant exercise price					$ 4
Warrant term description					From expiration dates ranging from April 27, 2021 to January 31, 2022 to a new expiration date of February 8, 2022.
Subsequent Event [Member] | Consulting Agreements [Member]
Warrant vested term	5 years
Warrant to purchase common stock issued in period	25,000
Warrant exercise price	$ 4
Accrued liabilities	$ 30,000
Subsequent Event [Member] | Exchange Agreements [Member]
Warrant vested term		5 years
Warrant to purchase common stock issued in period		58,334
Warrant exercise price		$ 4
Subsequent Event [Member] | Exchange Agreements [Member] | February 2017 and March 2017 [Member]
Performance-based cash bonuses					$ 402,500
Subsequent Event [Member] | Exchange Agreements [Member] | Consultant [Member]
Warrant vested term	5 years
Warrant to purchase common stock issued in period	10,000
Warrant exercise price	$ 4
Number of common stock shares exchanged	10,000
Subsequent Event [Member] | Exchange Agreements [Member] | Scientific Advisory Board [Member]
Accrued liabilities		$ 175,000
Number of common stock shares exchanged		58,334
Subsequent Event [Member] | Exchange Agreements [Member] | Four Non-Employee Directors [Member]
Warrant vested term		5 years
Warrant to purchase common stock issued in period		88,334
Warrant exercise price		$ 4
Accrued liabilities		$ 265,000
Number of common stock shares exchanged		88,334